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Epigenome regulates gene expression without changing the order of nucleotide sequences 
in DNA and has been confirmed to be involved in enormous numbers of biological processes 
including cell proliferation and differentiation, DNA replication and repair, and disease 
development. It is of medical relevance to further our understanding of the complex network of 
epigenomic regulation and apply the knowledge in disease diagnosis, prognosis, and therapy 
development. Eventually, profiling and screening personal epigenome can make a crucial part in 
precision medicine. Current investigating methods of epigenome usually start with a large number 
of cells and rely on manual processing of massive numbers of sample preparation prior to data 
readout, unrealistic in clinical settings where sample sizes may be limited, user qualification may 
vary, and human resources may also be inefficient. Signals from single cells are also buried due to 
bulk processing, limiting the application of these powerful assays in heterogeneous epigenome 
mapping. Thus, automating epigenomic assays using droplet microfluidics were proposed, aiming 
to utilizing the favorable features of droplets to approach flexible sample-sized, automated 
epigenomic assays starting directly from cells for qualified clinical usages.  
The first trial was using droplet microfluidics to automate samples preparation for an assay 
probing nucleosome positioning called MNase-seq. Using a droplet microfluidic device to 
encapsulate cells with lysis and digestion reagent, cellular chromatin was digested extensively to 
mononucleosomes (yield at ~ 80%) with sample sizes ranging from 125,000 cells to 2,500 cells. 
Next-generation sequencing of purified mononucleosomal DNA from these samples validated the 
efficacy of this platform to generate qualified samples for nucleosome mapping with results in 
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consistency with literatures. Clinical samples from 5 pairs of septic shock patients and matched 
non-septic controls along with 3 healthy controls (buffy coat extracted directly from whole blood) 
were also successfully processed by the same strategy and the sequencing results conveyed 
diagnostic values from the identified nucleosome positioning. More patients need to be enrolled 
to continue the clinical study to further validate the clinical relevance of nucleosome mapping from 
samples generated droplet microfluidically. 
To push forward the droplet microfluidic sample preparation, another device capable of 
preparing two samples for two different assays from the same cell sample was designed and 
characterized. Using a bifurcating channel design, droplets were aliquoted randomly to two 
directions allowing digestion of chromatin to different extents. Nucleosome-depleted regions as 
well as nucleosomal regions were both recovered for the detection of accessible regions and 
nucleosome locations, respectively. qPCR quality control results confirmed the enrichment of 
nucleosome-depleted, linker regions where regulatory sequences are located from the samples 
prepared on the device (fold change ≥5). Both cell line cells and clinical samples were processed 
with the optimal design for sequencing to achieve a final validation.  
Besides chromatin processing and related assay automation, chromatin 
immunoprecipitation (ChIP), the gold standard probing DNA-protein interaction, was also 
transformed to droplet microfluidics. The preliminary results confirmed that the conditions on the 
droplet microfluidic device were compatible with ChIP. Further optimization was required to 
improve the enrichment of targeted regions from ChIP DNA collected out of the droplet 
microfluidic device. The automation level of the entire workflow also needed enhancement by 
integrating the immunoprecipitating device with the immuno-bead conjugate wash device.  
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Chapter 1 Introduction 
 
Epigenetics 
The biologist Dr. Conrad H. Waddington conceptualized “epigenotype” in the early 1940s 
and described it as the whole complex of developmental processes connecting the genotype and 
the phenotype, informally defined the research field of epigenetics as the study of changes in gene 
function that are heritable and that do not involve any changes in the sequence of DNA.1-3 Ever 
since that, epigenetics has developed into one of the most popular research fields. Increasing 
amount of efforts have been made yielding extraordinary discoveries in elucidating the significant 
roles epigenetic marks play in the regulation of gene activity, cellular phenotypes, and disease 
development including cancer.4 The reversibility and the medical relevance of epigenome have 
attracted increasing amount of interest over the years, especially the potential of translating 
epigenetics to precision medicine, one of the most exciting directs in modern healthcare.  
Common Epigenetic Marks. The reason for the fact that a single genome gives rise to various 
cell types within an organism is the mediation of gene expression from the epigenetic marks and 
regulators to adjust the set of proteins that are expressed and determines the fate of the cell.4 Many 
common epigenetic marks function via controlling the accessibility of cellular molecules to the 
chromatin. Some epigenetic marks such as regulatory noncoding RNA (ncRNA) can also modulate 
targeted genes via different mechanisms5, 6, e.g., microRNA functions as antisense RNA degrading 
mRNA to negatively regulate the targets at a post-transcription level7, 8. This chapter will focus on 
the majority of the most studied epigenetic marks that control gene expression mainly through 
2 
 
reshaping conformation of chromatin, the essential medium for epigenetic regulation.9 These 
marks are deposited, recognized, and erased by specific enzymes or proteins to acquire the 
inheritance and reversibility of epigenome.4  
Chromatin is a packed format of nucleosomes which are the basic units of DNA 
compaction. Each nucleosome contains an octamer core of histone proteins H2A, H2B, H3, and 
H4 with a 147-bp DNA sequence wrapping around.10, 11 Both nucleosome constituents carry 
epigenetic marks including chemical modifications and variants. For DNA, methylation of 
cytosine or 5-methylcytosine (5-mC) is the first and most well-studied epigenomic modification 
with the structure identified in 194812 and the function of epigenomic significance established in 
197513, 14. General perception of the function of DNA methylation is blocking transcription 
initiation and silencing gene expression when it occurs in the immediate vicinity of transcriptional 
starting sites (TSSs). The full scope of DNA methylation functions is more complicated as it is 
context-dependent.15 DNA methylation is deposited by DNA methyltransferases, recognized by 
specific domain containing proteins such as methyl-CpG-binding domain (MBD) containing 
proteins, and removed by DNA demethylases.16 Additionally, oxidized derivatives of 5mC 
including 5-hydroxymethylctosine (5-hmC)17, 18, 5-formylcytosine (5-fC)19, and 5-
carboxylcytosine (5-caC)19, 20 may also have regulating functions and biological consequences.21 
For histones, various modifications of the highly basic amino-terminal tails have been identified 
including methylation, acetylation, phosphorylation and more22, among which methylation and 
acetylation on histone H3 are better explored with the former occurring mainly on lysine residues 
and the latter on lysine and arginine residues.23 It has been generally identified that H3K4me3 
(trimethyl-lysine 4 of H3) is associated with gene activation, H3K4me2 and H3K4me1 are 
enriched at enhancers or just downstream on active genes of H3K4m3, while trimethylation on 
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H3K9 and H3K27 are related to repressed gene expression.24 Histone acetylation generally 
activates gene expression as it neutralizes the positive charges on histones, thus attenuates the 
otherwise strong interaction between positive-charged histones and negative charged DNA strands, 
relaxing the chromatin structures to be more accessible. Histone acetylation can also be recognized 
by specific proteins and trigger corresponding pathways.25 Histone methyltransferases, 
demethylases, acetyltransferases, and deacetylases are responsible for the deposition and removal 
of these two marks, and specific domain containing reader proteins can differentiate these marks 
and bind accordingly.16 Besides tail modifications, histone variants replace the canonical H2A and 
H3 and changes the properties of nucleosomes, thus also influence all chromatin-based functions 
including gene expression and DNA repair.26, 27  
Not only the components of nucleosomes carry epigenomic marks, the positioning of 
nucleosomes is also an important epigenomic regulator of gene expression.28 Simply speaking, 
nucleosomes distribute continuously and randomly within gene bodies to stabilize the genes while 
usually are depleted from the TSSs regions of active genes forming nucleosome-free regions (NFR) 
or nucleosome-depleted regions (NDR) and occupy specific locations immediately up- and 
downstream of these TSSs to allow the binding of transcription factors.10, 29 Hence mapping 
nucleosome positioning patterns, especially their dynamic changes, reveals crucial information on 
chromatin function and gene regulation.28-30  
 As the understanding of these epigenomic regulators becomes further, it has now become 
clear that it is the complex interplay among epigenetic marks that shapes or maintains 
corresponding pathways and regulates nucleosome positioning and occupancy, thus alters 
chromatin accessibility and affects gene expression level.9 For example, CpG-island (a stretch of 
DNA where the occurring frequency of CG dinucleotide sequence is higher than other regions. “p” 
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stands for the phosphodiester bond connecting C and G) containing promoters of active genes 
usually lack DNA methylation and have NFR or NDR, with surrounding nucleosomes popularly 
marked with H3K4me3 and commonly accompanied by the replacement of H2A with lysine-
acetylated H2A.Z as such variant allows easier dissemble of or access to the nucleosome 
structure.26, 31 On the other hand, DNA methylation and H3K27me3 are almost mutually exclusive 
silencing genes via two different mechanisms, while H3K9me plays a key role in cross talking 
with and maintaining DNA methylation to ensure gene stability.9, 32-34 Therefore, it is important to 
overlay profiles of multiple epigenomic marks genome wide or at specific locations to fully explain 
their regulating mechanisms on gene expression under various cellular statuses.  
Epigenomic Impact on Disease Development and Treatment. Since epigenetic marks 
communicate with each other to form a complex regulating network of gene expression, any 
genetic, environmental, and metabolic stimuli that influences single or multiple participants of 
epigenome may cause dysregulation of genome and in turn causes phenotype abnormality and 
disease development.4 For example, p53-mutated cells (e.g., cancer cells) accumulated EZH2 
(enhancer of zeste homolog 2, a histone-lysine N-methyltransferase) to increase H3K27me3 which 
induced chromatin compaction and heterochromatin formation, leading to increased resistance to 
DNA damage.35 This epigenomic regulating pathway thus serves as one of the mechanisms 
modulating cancer cells’ resistance to chemo- and radiotherapies. Additionally, tumor hypoxia 
reduced the activity of TET (ten-eleven translocation enzymes), leading to reduced 5-
methylcytosine oxidization. This contributed to promoter hypermethylation at tumor suppressor 
genes, inhibiting their expression and providing a substrate for oncogenic events in solid tumors.36 
Besides cancer, epigenomic impact has also been found in other diseases such as sepsis, where the 
dynamic nucleosome positioning induced by the deposition and removal of positive and negative 
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histone marks remodeled the chromatin and controlled the induction and silencing phases of TNF-
α and other inflammatory cytokines during the course of sepsis development.30, 37  
As they are heavily involved in pathogenesis with the feature of reversibility, epigenomic 
marks have naturally became promising targets in diagnosis, prognosis, and therapeutics: altered 
or dysregulated epigenome patterns may indicate diseased statuses, and they may be 
reprogrammable to a healthy one.25 Recently, CpG island methylation phenotype (CIMP) was 
identified as a strong risk indicator of treatment response and survival rate for patients with 
pediatric T-cell acute lymphoblastic leukemia (T-ALL) or relapsed BCP-ALL (B-cell precursor 
acute lymphoblastic leukemia). Patients with low global methylation level at the promoter CpG 
islands (CIMP-) had significantly inferior response to treatment with lower survival rate and higher 
relapse rate compared to CIMP+ patients.38-40 Similarly, repressive mark H3K9me3 has also been 
pinpointed as a strong biomarker candidate and H3K9 demethylases as potential anti-cancer 
treatment targets. Globally enhanced H3K9 demethylase level and low H3K9me3 level was 
associated with melanomagenesis as such pattern allowed escape of oncogene-induced senescence. 
Inhibition of H3K9-active demethylases such as LSD1 and JMJD2 family members, however,  
rapidly restored senescence and thus controlled tumor growth.41 Moreover, histone acetylation and 
corresponding removers histone deacetylases have already served as targets of histone deacetylase 
inhibitors (HDACi) for treatment of multiple diseases including T-cell lymphoma, multiple 
myeloma, and sepsis with several FDA-approved HDACi products.25, 42 In the case of sepsis, 
HDACi functioned as anti-inflammatory reagent to protect the host, reduced the (over-)expression 
of critical immune receptors and antimicrobial products with a possible mechanism of increasing 
expression of the transcriptional repressor Mi-2β and enhancing the DNA-binding activity of the 
Mi-2/NuRD complex that repressed macrophage cytokine production.43 As time goes by, more 
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epigenomic marks and regulators are being discovered, characterized, and included into the pools 
of potential prognostic indicators and drug targets, and related clinical development is undergoing 
at an extraordinary pace.25  
Current Techniques Probing Epigenome and the Limitations. To investigate key epigenomic 
mechanisms impacting human health and validate epigenomic pattern changes after treatment, a 
variety of protocols have arisen to profile different aspects of epigenome for a thorough 
understanding of the embedded epigenomic landscape and infer causal relations among these 
epigenomic mechanisms.44 They are coupled to the rapid growth of NGS techniques and high-
throughput microarray platforms. 
DNA methylation is commonly detected via chemical modification followed by 
sequencing. Various bisulfite sequencing (BS-seq) strategies have been widely applied to locate 
and quantify DNA methylation distribution along genomic DNA (Figure 1-1). Whole-genome 
bisulfite sequencing (WGBS) treats DNA with a bisulfite reagent to convert cytosine to uracil 
while leaving 5-mC and 5-hmC intact. Sequencing is then conducted to profile genome-wide 
methylation on a single nucleotide level.45-49 Reduced representation bisulfite sequencing (RRBS) 
decreases cost and improves efficiency of WGBS by digesting samples with restriction enzymes 
(e.g. MspI and BglII) to selectively enrich CpG-containing regions and extracting the fragmented 
DNA with appropriate sizes (<600 bp) prior to bisulfite treatment.50-52 WGBS and RRBS cannot 
differentiate 5-mC from 5-hmC, though. Tet-assisted bisulfite sequencing (TAB-seq) specifically 
detects 5-hmC at single-base resolution, determining its abundance at each modification site by 
protecting hydroxymethyl- group with glycosylation and oxidizing other cytosine residues with 
Tet enzyme, the result of which leaves only 5hmC unaffected upon bisulfite treatment.19, 53, 54 
Another modified BS strategy, oxidative bisulfite sequencing (oxBS-Seq), is also capable of 
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differentiating between 5-mC and 5-hmC by specifically oxidizing 5-hmC before bisulfite 
treatment to obtain a positive readout of pure 5-mC. 5-hmC readout is inferred by comparing 
oxBS-seq with parallel-run regular BS-seq data,.55, 56 Compared to TAB-seq, oxBS-seq does not 
require expensive enzymes and avoids the potential inefficiency in glycosylation of 5-hmC or 
enzymatic oxidization of 5mC.48, 56 However, oxBS-seq requires two runs of sequencing thus 
significantly increases the financial and data processing burden. Beyond techniques targeting 5-
mC and 5-hmC, strategies detecting 5-fC and 5-caC have also emerged, such as 5-fC chemically 
assisted bisulphite sequencing (fCAB-seq) for 5-fC mapping and chemical modification-assisted 
bisulphite sequencing (CAB-seq) for 5-caC mapping.57 As a consequence of their relative newness, 
these techniques have limited established results compared to those for 5-mC and 5-hmC. 
With the applications of these detection methods, the mechanisms of DNA methylation 
regulating gene expression have been further understood. WGBS and RRBS have been used to 
reveal dynamic methylome changes upon effects from non-shared or unique environmental 
factors,58 map genome-wide DNA methylation in mammalian ovaries,59 and track genome-wide 
DNA methylation reprogramming and resulted biological consequences during mouse primordial 
germ cell expansion and migration.60 TAB-seq and oxBS-seq have been used to understand the 
biological functions of 5-hmC in cellular memory reprogramming, cancer development, and other 
diseases61-64. Moreover, BS-seq based strategies have been undergoing modification and 




Histone modifications as well as DNA methylation can be detected through affinity-
based methods followed by sequencing. In addition to chemical-based methods, affinity-based 
protocols using antibodies to specifically recognize modifications of interest on DNA-associated 
histone proteins and DNA methylation have been developed and widely used in laboratory 
epigenetic research (Figure 1-2).  
Methylated DNA immunoprecipitation (MeDIP) was developed to enrich 5-mC DNA 
regions with the highly efficient binding from 5-mC directed antibodies. The enriched product is 
then sequenced, leading to a powerful MeDIP-seq strategy that generates high-resolution whole-
genome DNA methylation profiles.65, 66 Similarly, antibodies targeting 5-hmC, 5-fC, and 5-caC 
have also been utilized to locate respective modified cytosine residues, providing multiple variants 
of DIP-seq strategies (i.e., hMeDIP-seq, 5-fC-DIP-seq, and 5-caC-DIP-seq).67-69 Methods using 
methyl-CpG binding domain (MBD) of methyl-CpG binding domain protein 2 (MBD2) to 
precipitate methylated DNA regions have also been applied to identify DNA methylation pattern 
integrated with sequencing (i.e. MBD-seq based methods).70-72 Critical roles of DNA methylation 
Figure 1-1 Selected protocols of chemical modification-based DNA methylation detections. 
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and its variations in regulating chromatin accessibility, altering gene expression and affecting 
disease/caner development have been clarified by applying one or multiple of these methods to 
reveal their distribution and changes along the reference genome sequences.63, 73-75  
Affinity-based immunoprecipitation was also applied to analyze chemical modifications 
(e.g., methylation and acetylation) as well as binding of transcription factors and chromatic 
remodeling complexes to histones that influence transcriptional regulation. The gold standard for 
such protein-DNA interaction is chromatin immunoprecipitation followed by sequencing (ChIP-
seq) (Figure 1-2, right protocol analyzed with sequencing). ChIP-seq generally involves (1) 
optional crosslinking of DNA and proteins to preserve their dynamic interaction if not strong, (2) 
shearing of chromatin into mono- and di-nucleosome sizes (about 150-300 bp) by sonication 
and/or micrococcal nuclease, (3) immunocapture of the modification of interest with specific 
antibodies, and (4) purification of captured DNA for library preparation and sequencing.76-78 The 
quality of the sequenced results can be assessed by comparing to a control library obtained with 
nonspecific antibody following the same protocol. Due to the size heterogeneity resulting from 
inconsistencies in DNA shearing and potential contamination from nonspecific-bound DNA, etc., 
conventional ChIP-seq suffers from low resolution in target mapping, and may not provide a 
complete set of protein binding locations.48 Additionally, a lack of normalization protocols that 
would allow for quantitative comparison between samples is also a shortcoming of this powerful 
method.79, 80 
To address these issues, variations of ChIP-seq have been constructed. ChIP-exo utilizes 
exonuclease treatment to narrow the region of protein binding on ChIP DNA sequences, enhancing 
mapping resolution of bound locations to the single-nucleotide level.79 ChIP with reference 
exogenous genome (ChIP-Rx) allows normalization of sequencing reads across cell populations 
10 
 
by adding a defined quantity of a reference epigenome on a per-cell basis, thus enabling 
quantitative comparison among multiple ChIP-seq runs.80 Although they are utilized on 
macroscale of samples commonly and still contain space for further optimization, ChIP-seq and 
derivative methods allow for identification and validation of modifiers and regulators related to 
aging, cellular development, disease progression, and other crucial biological processes, along 




Figure 1-2 Selected protocols of affinity-based chromatin modification detections. 
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Nucleosome distribution and open chromatin can be assessed by enzymatic and 
chemical processing followed by sequencing. Various methods have been developed to map 
these important features exploiting different enzymes and chemicals to expose nucleosomal or 
regulatory regions of interest (Figure 1-3).  
Micrococcal nuclease (MNase) is an endo-exonuclease that has long been used to digest 
chromatin with minimal sequence preference into (mono-)nucleosomes as it cleaves exposed DNA 
ends until encountering a barrier (e.g., nucleosome).87, 88 Combining MNase digestion with high-
throughput sequencing (MNase-seq) enables localization of DNA-binding proteins (e.g., 
transcriptional factors) and nucleosome positioning at superior resolution as high as single base 
pair.89 DNase-seq, on the other hand, exposes non-occluded accessible regions on genomic 
sequences by limited digestion of the endonuclease DNase I, characterizing the opposite regions 
on the genome when compared to MNase-seq.90 This allows the mapping of genetic cis-regulatory 
elements (e.g., promoters, enhancers, and silencers) in open chromatin structures, which reveals 
dynamic changes of acquisition and loss of transcription competence of genes.91, 92 Both MNase-
seq and DNase-seq separate enzymatic processing of chromatin from adaptor ligation to purified 
DNA. Recently, an assay for transposase-accessible chromatin using sequencing (ATAC-seq) has 
been developed, utilizing hyperactive Tn5 transposase to fragment chromatin and tag DNA with 
sequencing-compatible adaptors simultaneously.93 ATAC-seq enables fast and potentially 
simultaneous genome-wide mapping of active regulatory elements, nucleosome positioning, and 
chromatin accessibility, thus has gained growing popularity.94  
Apart from enzymes, chemicals can also be used to process chromatin. When treating 
chromatin with formaldehyde, a common crosslinking reagent, nucleosome-depleted regions 
obtain lower efficiency as fewer proteins are available to be chemically bonded with DNA 
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sequences comparing to nucleosome-occupied sites. Therefore, nucleosome-depleted DNA is 
enriched to aqueous phase after phenol-chloroform extraction. This leads to a strategy named 
formaldehyde-assisted isolation of regulatory elements (FAIRE).95 FAIRE-seq provides insight on 
active regulatory elements abundant in open chromatin, serving as another alternative to DNase-
seq and ATAC-seq without the necessity of relying on any enzymatic digestion.96  
When applied individually and integratedly to studies, these methods have enhanced the 
community’s understanding in the dynamics of and relation between nucleosome occupancy and 
chromatin remodeling during various biological processes and disease development, including 




Epigenomic marks can also be evaluated by hybridization-based technologies. 
Sequencing-based methods have revolutionized our understanding of epigenetic regulation on a 
genome-wide level. However, translating these protocols to large clinical cohorts can prove 
challenging, where cost, throughput, and reproducibility all become necessary considerations.  As 
Figure 1-3 Selected protocols to analyze nucleosome distribution and open chromatin. 
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a result, hybridization-based oligonucleotide microarray method has been developed for more 
cost-effective detections.52 Microarray methods have grasped wide popularity in detecting DNA 
methylation and histone modifications, where they have been used to assess the progression and 
effects of adiposity100, quantify metabolism’s contribution to tumor development101, mapping 
DNA methylome footprint during B cell differentiation102 and lung cancer103, and more. This 
popularity is reflected in the fact that a variety of commercial kits are available to researchers. The 
representative product is the Infinium Methylation Assays from illumina. Infinium 
HumanMethylation450 BeadChip Kit (referred to as 450 kit below, recently replaced by Infinium 
Methylation EPIC Kit) provides more than 485,000 methylation cites per samples at single-
nucleotide resolution across the genome. Upon bisulfite treatment, the assay interrogates the 
chemically modified sites with two probes differentiating methylated and unmethylated loci, 
allowing analysis of up to 96 samples simultaneously. Tiling microarray assays that combine 
immunoprecipitation or chemical modification with hybridization include ChIP-chip, MeDIP-chip, 
and DNase-chip (“chip” indicates microarray in the denomination, also seen in Figure 1-2 and 3). 
After targeting and isolating DNA associated with modification of interest via ChIP, bisulfite 
treatment, or other chemical modification methods as mentioned above, purified DNA hybridizes 
with complimentary probes to be identified instead of being sequenced. Applications of these 
arrays are commonly found in a host of studies including identifying specialized chromatin 
domains in transcriptional regulation104, recognizing protein markers for psychiatric disorder 
development105, and marking cell-specific epigenomic sites.106  
Translating Lab Technologies to Clinical Settings. Among all the epigenomic markers that have 
been investigated with the various methods introduced above, DNA methylation is the most 
commonly studied epigenetic marker in mammalian genomes.107 Commercially available assays 
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aimed to lower the experimental burden through increased automation and reduced manual 
processing have been developed to study DNA methylation in clinical settings.108, 109 Hence, the 
focus of the discussion below will outline research efforts to date aiming at automating the analysis 
of protein-DNA interactions with the goal of ultimately translating these technologies into a 
clinical setting. 
Limitations of ChIP-seq and Variants. While ChIP-seq and its variants have traditionally 
been the work horse for protein-nucleic acid interactions, these protocols have limitations that 
prevent their use in clinical settings besides those discussed above when introducing ChIP-seq and 
its derivatives. One major challenge is the large input sample size requirement. Traditionally, 
ChIP-seq requires more than 106 cells as starting materials for one mark to ensure effective 
enrichment of related DNA, which is unfeasible for small sizes of clinical samples or 
subpopulations of rare cells.110 A second challenge is the lack of sensitivity to cell heterogeneity. 
Epigenome is dynamic, tissue specific, and even single-cell specific especially in situations where 
cell heterogeneity is common (e.g., tumors).111, 112 Due to the aggregation of DNA from all cells 
present in the sample of interest, conventional ChIP buries possible signals from small numbers of 
cells carrying abnormal or novel features.113, 114 Third, robustness and reproducibility of ChIP-seq 
need to be enhanced. ChIP-seq experiments require high-quality chromatin, validated antibodies, 
carefully selected commercial kits for ChIP DNA purification, and the appropriate tubes for ChIP 
DNA preservation.115 They also rely largely on an operator’s skill to complete a large number of 
manual processing steps making the protocols lengthy and cumbersome. Fourth, ChIP-seq 
experiments are inherently low throughput, where they target only one protein or modification per 
sample volume. When combined, these factors complicate the use of conventional ChIP-seq in 
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routine clinical practices that study large patient cohorts such as monitoring both healthy and 
abnormal samples across human life span.52  
Efforts have been made to improve conventional ChIP-seq by reducing cell numbers, 
shortening DNA preparation time, and improving easeness/reducing sample loss by doing as many 
steps in a same tube as possible or carrying out the procedure in 96-well plates.116-119 However, 
none of these examples reduced the large numbers of steps needed or automated the entire ChIP 
process, nor did they allowed single-cell studies.  
Promising Approaches of Automated Epigenomic Analysis. Recent research efforts 
have turned to microfluidic tools as powerful alternatives to macroscale methods when it comes 
to develop an automated ChIP-seq platform. It is now widely known that microfluidics offers 
miniaturization of reagent volume, capability of parallelization and integration, and potential of 
automation, which are all particularly well-suited to sample-constrained, labor-intensive, and 
operator-dependent epigenetic analyses.120 Additionally, because of the microscale sizes, 
microfluidics facilitates single cell analysis, which will benefit investigation of cell epigenomic 
heterogeneity that has mostly been averaged out when using macroscale methods. The toolbox of 
single cell manipulation and processing on microfluidics has been expanding in the past few years 
with the emergence of fantastic proof-of-concept work including highly efficient single cell 
encapsulation in microfluidic droplets (Figure 1-4a)121, high-throughput single cell reverse 
transcription PCR (RT-PCR) (Figure 1-4b)122-124, and single-cell sequencing with comparable 
read count and improved sensitivity compared to tube-based protocols (Figure 1-4c).125-127 By 
adapting the relevant principles, many exciting studies have been completed to facilitate 




The Quake group has been piloting in enabling microfluidic low-input cells and single-cell 
epigenomic sequencing and profiling. They have developed automated microfluidic device-based 
ChIP protocol (AutoChIP) that allows ChIP DNA enrichment from 2000 cells compared to 
conventional methods.128, 129 Multi-layered and valve-assisted ring structures were designed to 
control sample loading, bead washing, and DNA eluting. By integrating multiple AutoChIP 
structures, they have also achieved a high throughput, automated microfluidic device for ChIP 
(HTChIP) capable of processing 10,000-cell equivalent chromatin samples in each parallel 
structure, running 14 ChIP and 2 controls simultaneously (Figure 1-5a).130  
The Lu lab has also been developing epigenomic assays for fewer cells by exploiting 
microfluidic chamber structures. By using valves to control chromatin loading and capture DNA 
elution, they have shown that fragmented chromatin from 100 cells can be treated microfluidically 
Figure 1-4 Selected microfluidic tools for epigenomic analysis. (a) Ordered single-bead (top) and 
single-cell encapsulation (bottom).121 Scale bars: 100 µm. Adapted from Ref 121 with permission 
of The Royal Society of Chemistry. (b) Single cell droplet array RT-PCR. Fluorescence images of 
droplet array at different thermal cycles. The input of mir-122 in each 6×6 array was 9.6×108 (left 
lane1, top three droplets), 9.6×107 (left lane1, bottom three droplets), 9.6×106 (lane 2), 9.6×105 
(lane 3), 9.6×104 (lane 4), 9.6×103 (lane 5), 9.6×102 (lane 6, top three droplets) and 0 copies per 
droplet (lane 6, bottom three droplets), respectively.122 Adapted from Ref 122 with permission of 
The Royal Society of Chemistry. (c) Cells and reagent encapsulation in DNA barcoding-single 
cell whole transcriptome sequencing with droplets.126 Scale bar: 100 µm. Adapted from Ref 126 
with permission of Elsevier. 
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with high enough quality for subsequent DNA analysis (Figure 1-5b).131 Further integration of 
sonication and immunoprecipitation enabled on-chip shearing of chromatin in addition to DNA 
capture (Figure 1-5c).132 Later, they further modified the original design and obtained a fluidized-
bed-based device for parallel analyses on two histone marks with the same batch of sheared 
chromatin.133 
These promising examples show the potential of microfluidics to facilitate automated, low-
input and single-cell epigenomic studies. However, they have their own limitations. The 
microfluidic chamber-based devices such as those from the Quake lab and the Lu lab, though 
allowed low-input samples, limited the sample size or antibody-functionalized beads number by 
an intrinsic factor: the device size. Only the specific volume of cell suspension or fragmented 
chromatin that fits the chamber can be processed, otherwise part of the samples had to be 
proactively expelled causing inevitable sample loss; only the amount of chromatin that is 
optimized against the number of beads loaded into the device can be processed, otherwise the 
immunocapture efficiency would be jeopardized. Thus, such design limits the sample size to the 
smaller end and has low flexibility/tolerance of sample size variance. Moreover, fabrication and 
operation of these multi-valved devices is complicated and thus not user-friendly. To improve on 
these aspects, another format of microfluidics, droplet microfluidics, may represents a better option, 
as droplets can be continuously generated allowing flexible sample sizes or magnetic bead 
numbers. Indeed, the Weitz lab and colleagues have applied droplet microfluidics to achieve 
automated single-cell ChIP-seq (Drop-ChIP) that can handle samples with indeterminate sizes and 
process thousands of cells individually within minutes. Starting with single cell encapsulation 
followed by simultaneous introduction of chromatin fragmentation and DNA immunocapture 
reagents to cell-containing droplets, Drop-ChIP used DNA barcoding to identify different cells 
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and analyze a mixture of three different cell types at single-cell resolution using deconvoluted 
chromatin state mapping, leading to cell subpopulation elucidation (Figure 1-5d).134 The 
specificity and information content accuracy were acceptable, as ~50% of reads could be aligned 
to known positive sites, and coverage of aggregated reads from 50 cells was comparable to 
conventional profiles. On the other hand, the coverage per cell was sparse on the order of 1000 
unique reads. Additionally, this device only automated cell encapsulation with lysis/digestion 
reagent and DNA barcode indexing; the two key steps of immunoprecipitation and ChIP DNA 
extraction were still carried out manually off the device. Furthermore, potential repetitions in DNA 
barcoding introduced possible false identification of cell types, and thus could confound the results.  
 To summarize, droplet microfluidics is a promising technique for flexible sample sized 
epigenomic assays especially for low-input to single-cell samples. With the only available example 
of ChIP in droplets containing areas for improving, it will be exciting to apply this technique to 
the methodology development for various epigenomic assays with the motivation to automate 
them for practical applications in clinical settings and promote epigenomic diagnosis, prognosis, 
and therapeutics. A long-term goal is realizing droplet microfluidic-based, automated epigenome 
profiling and screening for every single patient, realizing precision medicine from the aspect of 






Droplet microfluidics is a rapidly developing interdisciplinary field of research combining 
physics, chemistry, biology, and microsystems engineering. It is becoming a valuable tool for 
various applications such as single-cell analysis, complex biological and chemical assays, 
diagnostics, DNA sequencing, and drug screening.136-140  
The basic principle to generate droplets is segmenting aqueous streams with a continuous, 
immiscible, and inert oil flow, and each droplet functions as an independent microreactor.141, 142 
Figure 1-5 Selected microfluidic devices for epigenomic analysis. (a) A ring-structured platform 
for performing high-throughput ChIP (HTChIP) screening measurements of 16 different targets 
simultaneously.130 Adapted from Ref 130 with permission of The Royal Society of Chemistry. (b) 
A microfluidic oscillatory washing–based ChIP-seq (MOWChIP-seq) device for epigenetic 
profiling with 100 cells.131 Adapted from Ref 131 with permission of Springer Nature. (c) An 
integrated device for on-chip sonication and immunoprecipitation.132 Adapted from Ref 132 with 
permission of The American Chemical Society. Further permissions should be directed to the 
ACS. (d) A droplet-based microfluidic device for single-cell ChIP-seq (Drop-ChIP) integrating 
cell encapsulation, reagents addition, and DNA barcoding to analyze thousands of cells at single-
cell resolution.134 Adapted from Ref 134 with permission of Springer Nature. 
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The volume of the droplets typically range from femtoliters to nanoliters, leading to extremely 
small reagent consumption suitable for rare samples such as stem cells and circulating cancer 
cells.143-149 Droplet sizes are tunable by changing flow rate values and ratios between continuous 
and dispersed phases.150 Droplet microfluidics also contains single cell analytical capability as 
individual cells can be encapsulated and processed in single droplets.121, 134, 151-156  
Reliable and precise manipulation of individual droplet has emerged recently covering 
droplet coalescence, splitting, injection, and content mixing.157-168 Additionally, previous studies 
have shown that mixing occurs very rapidly within the droplets due to convective flow profile 
inside and when assisted by serpentine design, allowing for more efficient chemical and biological 
reactions and thus shorter operation time for experiments.141, 169-171 This is highly advantageous 
over conventional continuous-flow microfluidics, which offers low Reynolds numbers and laminar 
flows, resulting in rather slower mixing predominated by molecular diffusion and would need 
additional mechanism for mixing.141    
 With all the favorable features discussed above, it is feasible to utilize droplet microfluidics 
to automate the entire workflows of epigenomic assays with size-flexible and low-input samples 
to approach the expectations in clinical applications. The various manipulations of droplets offer 
abundant options to miniaturize the massive manual processing involved in these assays. The 
potential for single cell analysis also opens the door for future epigenomic heterogeneity studies 
on size-limited samples. 
  
Dissertation Overview 
In this thesis, the current status of epigenetics and the motivation of using droplet 
microfluidics to automate epigenomic assays were discussed in Chapter 1. The devices used in this 
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thesis were designed, fabricated, and characterized with the detailed protocol described in Chapter 
2. Chapter 3 to 5 described the automation of sample preparation for three epigenomic assays 
(MNase-seq, MBA/MNase-seq dual assays, and ChIP-seq) using droplet microfluidics because of 
its favorable features including isolation of samples for reduced nonspecific binding, rapid mixing, 
sample scalability, and the potential for single cell studies. Overall, this thesis provided the 
beginning of automating various epigenomic assays in droplet microfluidics for practical 
applications. Preliminary results from clinical samples were discussed in Chapter 6, providing 
compelling evidence for the applicability of droplet microfluidic platforms in clinical epigenomic 
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Chapter 2 Design, Fabrication, and Operation of Droplet Microfluidic Devices 
 
Introduction  
One of the most common methods to generate prototypes of microfluidic devices in 
academic laboratories is soft lithography with poly(dimethylsiloxane) (PDMS). Ever since 
Whitesides’ group reported the successful fabrication of microfluidic channels with this technique 
in the 90s1, this rapid prototyping protocol with PDMS for microfluidic devices has obtained wide 
applications due to its favorable features including optical transparency, high biocompatibility, gas 
permeability, low cost, and ease of use.2, 3 This chapter describes the adapted protocol of soft 
lithography with PDMS for droplet microfluidic device fabrication for most of the work in this 
thesis in detail. The process of device fabrication in following chapters is the same as what is 
described here unless otherwise noted. 
 
Materials and Methods 
Materials 
Isopropanol  
Negative photoresist SU8 2025 and 2050 (MicroChem Corp, Westborough, MA) 
Propylene glycol monomethyl ether acetate (PGMEA) (Sigma-Aldrich, St. Louis, MO) 
 (Tridecafluoro-1,1,2,2-tetrahydrooctyl) trichlorosilane (Gelest, Inc., Morrisville, PA) 




Fluorinert FC40 (Sigma-Aldrich, St. Louis, MO) 
Aquapel (Pittsburgh Glass Works, LLC., Pittsburgh, PA) 
Novec 7500 engineered fluid (3M, St. Paul, MN) 
Surfactant (Perfluoropolyether polyethylene glycol block co-polymer, RAN 
Biotechnologies, Inc. Beverly, MA) 
Sodium chloride solution (3 mole/L, aqueous solution) 
Silicon wafers (University Wafer, Boston MA) 
UV lamp (Optical Associates, Incorporated) 
Hot plates (Cimarec, Thermo Scientific) 
Oven (HeraTherm Oven, Thermo Scientific) 
Spin coater (PWM 32, Headway Research, Inc) 
Long pass UV filter (PL360-LP, Omega Optical, Inc., Brattleboro, VT) 
Profilometer (KLA-tencor Alpha-Step IQ or Dektak XT Surface Profilometers) 
Forceps or tweezers 
Transfer pipettes 
Glass petri dishes 
Plastic petri dishes 
Blunt-tip biopsy needles 
Scotch Magic Invisible Tapes (3M, St. Paul, MN) 
Syringe filters w/ 0.2 µm PTFE membrane (VWR International, Inc) 
Microscope glass slide (Fisher Scientific, Inc.) 
Power supply (DC regulated power supply, TENMA T2-6628) 
In-house built DC-AC converter (12V DC input, 0-360V AC at 36 kHz as output) 
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Syringe pumps (Pump 11 Pico Plus Elite, Harvard Apparatus) 
High speed camera (Phantom Miro Ex2 or Phantom VEO 640L) 
Stereoscope or fluorescence microscope (Leica M80 or DMi8) 
Design and Fabrication of Masters 
Microfluidic patterns were designed with a computer-aided design (CAD) software 
program AutoCAD (AutoDesk, Inc.) and the cad files were sent to CAD/Art Services, Inc. 
(Bandon, OR) for photomask printing with the polarity of patterns being transparent and other 
areas covered with black ink (See Figure A-1 in Appendix A). Once photomasks were received, 
standard contact photolithography was conducted to generate masters.4 Depending on the 
thickness of the designed patterns and the effective power of the UV lamp, fabrication parameters 
including spin rate, spin duration, baking temperatures, and UV exposure duration were 
determined accordingly following the guidance of the photoresist vendor datasheet and testing 
trials. To obtain clean masters, it was preferred to execute the protocol in a cleanroom. A detailed 
fabrication process was described as below to obtain a master for the nucleosome preparation 
device used in Chapter 3 that contained patterns of different thickness (the pattern for the droplet 
formation and manipulation was referred to as the first layer, and the pattern for droplet delay was 




A silicon wafer was dried at 120 °C for 5 minutes. A quarter-sized SU8 2025 was aliquoted 
onto a 3-inch silicon wafer with a transfer pipette, and the wafer was centered onto the holder of a 
spin coater. A spin rate of 500 rpm for the duration of 10 seconds followed by a spin rate of 2000 
rpm for the duration of 30 seconds was operated to achieve a 40-µm layer. After soft baking at 
65 °C for 3 minutes and 95 °C for 6 minutes, respectively, the silicon wafer was set aside to cool 
down for 5 minutes. The first-layer photomask was aligned to the wafer, and a filter to cut off 
unnecessary wavelengths of light (<350 nm) was placed on top of the mask. Two weights made of 
iron were put at the edge of the filter to help tighten the contact of the mask to the photoresist. UV 
Figure 2-1 Fabrication workflow of microfluidic device masters using negative photoresist to 
construct two layers of patterns that are of different thicknesses. 
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exposure was completed with a UV lamp (Optical Associates, Incorporated) for 24 seconds 
(Figure 2-1, the first “UV exposure”). After the removal of the filter and photomask, the silicon 
wafer was set aside to rest for 5 minutes and transferred with forceps to complete post-exposure 
baking at 65 °C for 1 minutes and 95 °C for 6 minutes, respectively. After set aside and cool for 5 
minutes, the silicon wafer was immersed into propylene glycol monomethyl ether acetate 
(PGMEA) in a glass petri dish for 5 to 10 minutes to develop the uncured photoresist. During the 
development step, gentle agitation of the petri dish or the silicon wafer was favored to accelerate 
the dissolution of uncured SU8 2025. The wafer was rinsed thoroughly with fresh PGMEA and 
with isopropanol to ensure that no white cloudy material was formed, indicating that all uncured 
photoresist was removed. Then the wafer was blow dry with nitrogen and set aside to rest for 5 
minutes. The first layer was completed (Figure 2-1, “Developed first layer”). 
A quarter-sized SU8-2050 was aliquoted onto the wafer and spin coated at 500 rpm for 10 
seconds followed by 1150 rpm for 30 seconds to achieve a 160-µm layer. Then the wafer was soft 
baked at 65 °C for 7 min and 95 °C for 35 minutes, respectively. After set aside to cool down for 
5 minutes, the second-layer photomask was aligned (via visual estimation or a professional mask 
aligner with the assistance of overlapped patterns and/or align markers) to the existing pattern to 
ensure a correct connection of channels. Then the photomask was tightly contacted to the 
photoresist with the addition of the filter and iron weights. UV exposure was operated for 36 
seconds (Figure 2-1, the second “UV exposure”) and the wafer was set aside to cool down for 5 
minutes followed by post-exposure baking at 65 °C for 5 minutes and 95 °C for 15 minutes, 
respectively. After another 5 minutes of cooling down, the photoresist was developed in PGMEA, 
blow dry with nitrogen, and set aside for cool down as described before. The second layer was 
completed (Figure 2-1, “Developed second layer”).  
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The fabricated master was placed onto a room-temperature hot plate, which was then set 
to 200 °C. The master was kept on the hot plate for 10 min after it reached the targeted temperature. 
After that, the hot place was turned off and the wafer remained on the hot plate until it naturally 
cooled down to room temperature to avoid sudden thermal change induced contraction of SU8 and 
subsequent detachment of patterns. This step of hard baking was supposed to heal any potential 
cracks on the solidified SU8 patterns as well. The master was then placed in a plastic petri dish 
and put into a vacuum chamber to be treated with vacuum-assisted evaporated 100-µL 
(tridecafluoro-1,1,2,2-tetrahydrooctyl) trichlorosilane overnight. 
To check the fabricated patterns’ real thicknesses, a profilometer can be utilized to measure 
the height of interested planes. The profilometer’s stylus tip moves vertically to get in contact with 
a surface and scans over the surface with a preset contact force to record the vertical displacement 
variation cross a certain lateral distance. A profile like Figure 2-2 was constructed based on the 
scanned data showing the thickness of the first layer to be approximately 46 µm and the difference 
between the first and second layers to be approximately 94 µm, indirectly measuring the thickness 
of the second layer to be approximately 140 µm. The fabricated patterns had similar thicknesses 




Assembly of PDMS devices 
The microfluidic devices were fabricated by soft lithography as described in previous 
literature1, 5 with slight adjustment. A general workflow is shown in Figure 2-3. Briefly, PDMS 
base and curing agent were mixed at a mass ratio of 10:1 and degassed under vacuum before the 
mixture was poured over the fabricated device master in the last section (Figure 2-3, “Pour PDMS 
to form a stamp”). After being cured in an oven at 70 °C for at least 1 hour, PDMS stamps were 
cut and peeled off from the master. Holes of inlets and outlets were punched with blunt-tip biopsy 
needles and the stamps were sonicated clean in water for 5 min (Figure 2-3, “Peel off stamp to 
punch holes for tubing”). They were dried with nitrogen and cleaned with Scotch tapes. A 
degassed mixture of PDMS base and curing agent at a mass ratio of 10:1 was spread over a 
microscope slide on the spin coater at 500 rpm for 15 seconds followed by 1500 rpm for 30 seconds 
Figure 2-2 Profilometer measurement of a master with patterns of two different thicknesses. 
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and was subsequently half-cured in the oven at 70 °C for approximately 8 min (the duration should 
be empirically determined to ensure half cure of PDMS). Subsequently, the cleaned PDMS stamp 
was gently attached to the PDMS coated glass slide with mild pressing from a tweezer. The 
assembled device was then baked in the oven at 70 °C for at least 30 min before use (Figure 2-3, 
“Assemble device onto a flat surface”). 
 
Employment of Assembled Devices 
A PDMS device, when ready to use for experiments, was taken out of the oven and surfaced 
treated with Aquapel as described in previous literatures.6 Briefly the device was filled and 
incubated with Aquapel for ~ 60 seconds. Aquapel was expelled out the device by air. Then the 
device was rinsed with filtered FC40. Electrolyte channels were filled with sodium chloride 
solution (3 M). Two clamps from electrodes of an in-house built DC-AC converter (12V DC input, 
Figure 2-3 Workflow of microfluidic device fabrication by soft lithography using PDMS. 
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0-360V AC at 36 kHz as output) which was connected to a DC-regulated power supply were 
connected to the syringe needles supplying the electrolyte channels to form a complete circuit for 
the AC electric field. The device is placed on the holder of a stereoscope (Leica M80) or a 
fluorescence microscope (Leica DMi8). 
The components of the reagents delivered into the device depend on the specific 
experiments that are to be operated. Generally, aqueous reagents for droplet formation are supplied 
by 24G PTFE tubing (Cole-Parmer, Vernon Hills, IL) attached to syringes driven by one syringe 
pump. Novec 7500 engineered fluid, the fluorinated oil phase for droplet formation, is mixed with 
2% (w/w) surfactant and delivered to the device by a second syringe pump. Other reagents for 
additional manipulations of droplets are delivered to the device by additional pumps. Flow rates 
are optimized to ensure that droplets with appropriate size were generated and subsequent 
manipulations are carried out successfully. Droplets are monitored by a high-speed camera 
mounted onto the stereoscope or the fluorescence microscope. Products are collected to an 
Eppendorf tube for subsequent processing. 
 
Operations of Droplet Microfluidics 
Examples of basic droplet microfluidic operations that are utilized in this thesis include 
droplet formation, droplet delay, and reagent addition. Monodispersed droplets can be 
continuously generated at a frequency ranging from 100 Hz to > 103 Hz using common formation 
geometries such as a T-junction7 and a flow focusing8, 9 design. Demonstration of droplet 
formation were shown in Figure 2-4a and b with in-house built T-junction and flow focusing 
devices. The integrity of droplets is maintained by the protection from the surfactant that is doped 
in the continuous phase (oil) and adsorbed at the interface between droplets and the oil.10-12 This 
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enables droplets to travel for a certain duration without coalescence, and thus allows the 
completion of the physical, chemical and/or biological process inside (Figure 2-4c). Under the 
effect of an electric field, the dynamic instability of the surfactant layer at the interface between 
droplets and the continuous phase allows the addition of another stream of aqueous phase into the 
otherwise protected droplets (Figure 2-4d).13-15 
 
Previous studies have been trying to elucidate the mechanism and governing rules of 
droplet formation, and they have revealed that the flow rates and the viscosities of the participating 
Figure 2-4 Examples of droplet microfluidic operations at 8 µL/min of the oil and 2 µL/min of 
each aqueous stream for droplet formation using in-house built devices. (a) Time sequence of 
droplet formation in a T-junction geometry. Notice that the formation of one droplet took less than 
3×10-3 sec, indicating a formation frequency higher than 333 Hz. The black arrows indicated the 
liquid flow directions, and the red arrows indicated one specific droplet. (b) Droplet formation in 
a flow-focusing geometry. (c) Droplets remained the same in two delay channels that were 
separated by multiple others. (d) Reagent addition via the geometry of picoinjector into every 
single droplet. The flow rate of the injected stream was 1.2 µL/min. Scale bar represents 300 µm 
(a, b, and d) and 500 µm (c), respectively. 
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liquids8, 16-19, the dimensions of the channels18, 20, 21, and the type and the concentration of the 
utilized surfactant12, 22 all contribute to the final morphology and generating mechanism of the 
produced droplets.  In the case of a T-junction used under typical microfluidic conditions (flow 
rates on the order of 0.01 to 1 µL/s and the capillary number smaller than 10-2) and channel widths 
and heights on the order of 10 to 100 µm, a simple scaling rule (2.1) can be used to predict droplet 
sizes, where l is the length of the droplet (that blocks the forming channel), w is the width of the 
channel, Qd and Qc are flow rates of the dispersed and continuous phases respectively, and α is a 
constant that depends on the geometry of the T-junction.18 As shown in Figure 2-5, increasing the 
flow rate of oil decreased the flow rate ratio between the dispersed and continuous phases when 
the dispersed phase were delivered to the device at a constant total flow rate, leading to a reduction 
in the length of the droplets generated by the in-house T-junction device with a channel width of 
40 µm. The linear fitting yielded a high regression coefficient (R2 = 0.999) at a fixed intercept of 
40, evidenced that the in-house experimental setup of droplet generation with a T-junction has 










Figure 2-5 Adjusting droplet sizes by changing the flow rates of participating liquids. Qd was kept 
constant at 4 µL/min (2 µL/min of each aqueous stream coming to the formation junction) while 
Qc was changed from 4 to 12 µL/min at a 2 µL/min step. n ≥ 18 droplets for all conditions. 
 
Similarly, changing flow rates of the liquid also modulates the droplet formation rate when 
using the same design of T-junction.23 Increasing Qd or Qc accelerates the production rate of 
droplets, which is intuitively obvious as more materials are delivered to the same channel per unit 
of time (Figure 2-6). Notice that the production rate was on the order of 102 to 103 Hz and the 
generated droplet size was on the order of 102 pL, demonstrating the potential for droplet 
microfluidics to be exploited in the fields where high throughput and small, individual 




Figure 2-6 Production rate of droplets under different flow rates of the continuous and dispersed 
phases. (a) The Qd of the aqueous streams was kept constant at 4 µL/min. (b) The flow rate ratio 
between the dispersed and continuous phases was maintained at 2. n ≥ 18 droplets for all 
conditions. 
 
 Not only the sizes and the production rate of droplets can be controlled, the amount of 
material injected into each droplet can also be tuned when interdroplet spacing is the same for all 
droplets coming across the injecting site as an array.14 Increasing the flow rate of the to-be-injected 
aqueous stream while maintaining other conditions constant increased the amount of fluid added 




Figure 2-7 Injected volume of the to-be-injected aqueous stream under different flow rates (Qi). 
The flow rates of the dispersed (Qd) and continuous (Qc) phases for droplet formation were 
maintained at 6 and 8 µL/min, respectively. n ≥ 43 droplets for all conditions. 
 
Conclusion 
In this chapter, a complete workflow of implementing droplet microfluidic experiments 
has been introduced from the design of microfluidic device patterns to the common operations 
utilizing the devices. The presented data proved that in-house built devices fabricated with 
standard photolithography and soft lithography can generate expected results that have been 
established by previous literatures following the protocol explained here. Droplet formation, delay, 
and reagent injection were carried out successfully with common geometries including T-junctions, 
flow focusing, and picoinjectors.  Manipulating droplets carefully can be significant to control 
parameters that can contribute to background signals when developing quantitative assays while a 
wider range of droplet sizes, injected volumes, and other parameters are acceptable for other 
applications.29, 30 Therefore, the extent to adjust droplets depend on the applications, and the 
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protocol described in this chapter can serve as a general guidance to initiate droplet microfluidic 
device design and tests for subsequent assay development.  
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Chapter 3 A Droplet Microfluidic Platform for Efficient Enzymatic Chromatin Digestion 
Enables Robust Determination of Nucleosome Positioning 
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Abstract 
The first step in chromatin-based epigenetic assays involves the fragmentation of 
chromatin to facilitate precise genomic localization of the associated DNA. Here, we report the 
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development of a droplet microfluidic device that can rapidly and efficiently digest chromatin into 
single nucleosomes starting from whole-cell input material offering simplified and automated 
processing compared to conventional manual preparation. We demonstrate the digestion of 
chromatin from 2,500-125,000 Jurkat cells using micrococcal nuclease for enzymatic processing. 
We show that the yield of mononucleosomal DNA can be optimized by controlling enzyme 
concentration and incubation time, with resulting mononucleosome yields exceeding 80%. 
Bioinformatic analysis of sequenced mononucleosomal DNA (MNase-seq) indicated a high degree 
of reproducibility and concordance (97-99%) compared with conventionally processed 
preparations. Our results demonstrate the feasibility of robust and automated nucleosome 




In eukaryotic organisms, meters of genomic DNA must be compacted to fit into a micron-
sized cell nucleus.1, 2 This is accomplished by the formation of nucleoprotein complexes—termed 
chromatin for their readily stainable nature—that permit high packing ratios. However, this 
arrangement must still allow for controlled access to the DNA for template-dependent functions 
such as gene transcription, DNA replication, and repair.3-6 Dynamic and highly regulated 
compaction and decompaction of DNA reflects changes in the density of nucleosomes, the 
fundamental repeating unit of chromatin. With ~147 base pairs (bp) of DNA coiling around an 
octamer of histones H2A, H2B, H3 and H4, loosely organized nucleosomes form a beads-on-a-
string array structure connected by linker DNA.3-6 Nucleosomes usually occupy positions on DNA 
sequences that are correlated to specific functions.2, 3, 7 They are commonly depleted from active 
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promoter, enhancer, or terminator regions, forming nucleosome-depleted regions (NDRs) or 
nucleosome-free regions (NFRs) that allow for easier access of transcriptional machineries to these 
genes8, 9; while in intragenic regions nucleosomes have a more random and continuous distribution  
that is proposed to assist in maintaining genome stability by occluding DNA-binding proteins.4, 10 
Dynamic nucleosome repositioning occurs in response to cellular and environmental cues under 
the control of histone chaperones and chromatin remodeling complexes, which are regulated by a 
wide variety of mechanisms including, but not limited to, chromatin-binding factors and enzyme 
complexes, covalent modifications of DNA bases, histone and nonhistone proteins, as well as 
coding and noncoding RNA species.9  
Given their foundational role in chromatin organization, specific assays for nucleosome 
positioning can provide the most direct correlate of gene expression since their position is the 
integrated result of the interplay of the entire collection of DNA- and histone-modifications, and 
other regulatory mechanisms. A common nucleosome mapping approach involves chromatin 
digestion using micrococcal nuclease (MNase) to yield mononucleosomal DNA followed by next-
generation sequencing (MNase-seq)7, 11-13. MNase is a Ca2+-dependent endo-exonuclease that 
preferentially cleaves exposed linker DNA until it encounters a barrier such as a stably bound 
protein and/or a nucleosome where the histone core protects the packed DNA sequence from being 
digested.14, 15 Mono-, di-, and poly-nucleosomes are generated after chromatin digestion by MNase 
at appropriate concentrations for a certain period. Following next-generation sequencing of 
libraries directed to nucleosomal DNA from digested chromatin, mapping sequenced reads of 
(mono-) nucleosomal DNA to a reference genome localizes protein-binding regions and 
nucleosome positions at up to single base pair resolution.11 Furthermore, some form of controllable 
chromatin fragmentation is also critical for identifying NDRs/NFRs (e.g., by ATAC-seq16-18 and 
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FAIRE-seq19-21) and for determining the precise genomic position of regulatory proteins, as well 
as histone- and DNA-modifications (e.g., by ChIP-seq22-24). However, macroscale nucleosome 
preparation, and more generally all chromatin digestion assays, have drawbacks—particularly in 
terms of throughput and ease of use, which can limit applicability in the analysis of challenging 
and often sample-limited clinical specimens. We therefore set out to design a microfluidic device 
to automate MNase-based chromatin processing in a way that was automated and compatible with 
variable cell input amounts. 
Droplet microfluidics have emerged as a valuable approach for various biochemical assays, 
including single-cell analysis, diagnostics, DNA sequencing, and drug screening.25-28 The basic 
principle involves the segmentation of an aqueous sample with an inert, immiscible oil such that 
each of the resulting droplets functions as an independent microreactor.29, 30 The volume of the 
droplets typically range from femtoliters to nanoliters, leading to extremely small reagent 
consumption and amenability to rare samples, such as stem cells and circulating tumor cells.31-37 
Recent developments in the field have demonstrated exquisite control over fluid addition and 
removal, as well as droplet coalescence.38-46 Additionally, rapid mixing within droplets allows 
more efficient chemical and biological reactions, and corresponding shorter operation times.29, 47-
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     In this chapter, we describe the development and optimization of a droplet microfluidic 
device that efficiently digests chromatin to give a high yield of mononucleosomal DNA, which is 
the desired input material for ChIP- or MNase-seq applications. The automated device 
simultaneously lyses and digests whole cells to give product DNA that is indistinguishable from 
that obtained using benchtop processing. We also demonstrate the applicability of the approach to 
variable and very small cell inputs, with final validation achieved by genome-wide MNase-seq 
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analysis that, again, shows identical performance to bulk-processed cells. The additional validation 
of both PCR-free and PCR-amplified sequencing library construction makes this device of high 
potential value as the first step of sample preparation for a number of current and emerging 
epigenetic assays. 
 
Materials and Methods 
Microfluidic device fabrication 
Microfluidic devices were generated using standard photolithography and soft lithography 
methods with details described in Chapter 2. Transparent photolithography masks were designed 
in AutoCAD (Schematic shown in Figure 3-1) and then printed by CAD/Art Services, Inc. 
(Bandon, OR). Negative photoresists SU8 2025 and 2050 (MicroChem Corp, Westborough, MA) 
were deposited onto silicon wafers (University Wafer, Boston MA) according to manufacturer 
recommendations. Briefly, SU8 2025 was first spin coated (PWM 32, Headway Research, Inc) 
onto the silicon wafer at 2000 rpm for 30 seconds to give a 40-µm thick layer. After soft baking, 
the resist layer was exposed to a UV lamp (Optical Associates, Incorporated) through the first-
layer photomask. After post-exposure baking, the patterned wafer was developed in propylene 
glycol monomethyl ether acetate (PGMEA) (Sigma-Aldrich, St. Louis, MO) and dried under 
nitrogen. SU8 2050 was then spin coated onto the patterned wafer at 1150 rpm for 30 seconds to 
give a 160-µm thick layer. After soft baking, the resist was exposed to UV through the second-
layer photomask and then developed as described above. 
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Figure 3-1 Illustration of the photomask design of the device. The red parts are the first layer, and 
the black part the second. The two layers are printed on two individual masks. They should be 
aligned to ensure the connection of the channels (shown as the overlap between the red and black). 
Zoom-in insertions show the design for the filter and the picoinjector. 
 
Microfluidic devices were fabricated by casting poly(dimethylsiloxane) (PDMS) over the 
two-layer SU8 master. The PDMS base and elastomer curing agent (Momentive RTV 615 kit, R.S. 
Hughes, Carol Stream, IL) were mixed at a mass ratio of 10:1 and degassed under vacuum before 
the mixture was poured over the master. After curing for at least one hour at 70°C, PDMS replicas 
were cut and peeled from the master. Tubing inserting holes were punched with blunt-tip biopsy 
needles (18 gauge for inlets, 20 gauge for the outlet and electrolyte inlets). After punching holes, 
the devices were then sonicated in water for 5 min and dried with nitrogen to remove any PDMS 
debris. In parallel, a base layer was created on a glass slide by spinning a degassed, 10:1 PDMS 
base:elastomer mixture onto a glass microscope slide. This base layer was partially cured for 8 
53 
 
min before the microfluidic replica was placed on top with gentle pressure, followed by a final 30 
min bake to fully bond the microfluidic device.  
 
Microfluidic device operation 
Solutions were delivered to the chip through 24-gauge PTFE tubing (Cole-Parmer, Vernon 
Hills, IL) controlled by syringe pumps (Pump 11 Pico Plus Elite, Harvard Apparatus). The 
immiscible oil phase was the fluorinated oil Novec 7500 (3M, St. Paul, MN) with 2% (w/w) 
perfluoropolyether polyethylene glycol block co-polymer surfactant (RAN Biotechnologies, Inc. 
Beverly, MA). The tubing to deliver cells to the chip was treated with 1% (w/v) Pluronic F127 
(Sigma-Aldrich, St. Louis, MO)-containing PBS solution overnight and prefilled with PBS buffer. 
Electrolyte channels on the microfluidic device were filled with a 3M sodium chloride solution. 
Two clamps from electrodes of an in-house built DC-AC converter (12V DC input, 0-360V AC at 
36 kHz as output), which was connected to a power supply (DC regulated power supply, TENMA 
T2-6628), were connected to the syringe needles supplying the electrolyte channels to form a 
complete circuit for the AC electric field. 
Prior to experiments, microfluidic devices were treated with Aquapel (Pittsburgh Glass 
Works, Pittsburgh, PA) as described previously50 to give a hydrophobic coating throughout sample 
processing. Optiprep (Sigma-Aldrich, St. Louis, MO) was added to PBS buffer to obtain a final 
density of 1.07 g/mL at a 21.9% (v/v) concentration. Cells were resuspended in this density-
adjusted PBS buffer to reduce clumping and settling in the tubing. Cell suspensions were drawn 
into the pre-treated tubing separated from the pre-filled buffer by a plug of air. Lysis buffer (pH 
7.9) contained 10 mM HEPES, 1.5 mM magnesium chloride (MgCl2), 10 mM potassium chloride 
(KCl), and 0.5% (w/v) IGEPAL-CA630 (Sigma-Aldrich, St. Louis, MO). Digestion buffer (pH 
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7.5) contained 20 mM Trizma hydrochloride (Tris-HCl), 15 mM sodium chloride (NaCl), 60 mM 
KCl, 5 mM calcium chloride (CaCl2), 0.15 mM spermine, and 0.5 mM spermidine. Quenching 
buffer (pH 8) contained 100 mM Tris-HCl, 20 mM ethylenediaminetetraacetic acid (EDTA), 200 
mM NaCl, 2% Triton-X 100, and 0.2% sodium dodecyl sulfate (SDS). The combined lysis-
digestion buffer was prepared by mixing 30 µL MNase (2000 GU/µL; New England Biolabs, 
Ipswich, MA), 120 µL digestion buffer, and 300 µL lysis buffer.  
The fluorinated oil wets the hydrophobic channels preferentially and cuts the slower 
aqueous streams into droplets. Flow rates of oil (6 µL/min), cell suspension (2 µL/min), lysis-
digestion reagent (2 µL/min), and quenching buffer (4 µL/min) were optimized to ensure that 
droplets with appropriate size were generated and quenching buffer was injected into every droplet. 
Droplets were collected via a 30-gauge PTFE tubing (Cole-Parmer) into a 1.5-mL tube (Eppendorf 
DNA LoBind, Fisher Scientific, Waltham, MA). Device operation was visualized using a high-
speed camera (Phantom Miro Ex2) mounted onto either a stereoscope (Leica M80) or microscope 
(Leica DMi8). 
 
Preparation of off-chip control samples 
To prepare off-chip samples for comparison with those processed on-chip, an identical 
volume of cell suspension was added to a clean 1.5-mL tube and mixed with an equivalent volume 
of combined lysis/digestion buffer. Digestion was performed in bulk for the same time as droplets 
were incubated on-chip for enzymatic processing, and the reaction was similarly stopped by 
addition of quenching buffer. 
 
Cell Culture and Sample Preparation 
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Jurkat acute T-cell leukemia cells (Clone E61, ATCC® TIB152, American Type Culture 
Collection, Manassas, VA) were cultured at 37°C with 5% CO2 in the vendor recommended media 
(RPMI-1640 supplemented with 10% v/v fetal bovine serum). The cells were pelleted at 800×g 
for 5 min at 4°C, washed with cold PBS buffer, and resuspended into the density-adjusted PBS 
buffer to a defined concentration, as described below. After resuspension, cells were stored on ice 
until chromatin digestion. Digestion experiments were carried out with 30 µL volumes of cell 
suspension, unless otherwise stated.  
 
Characterization of fragmented chromatin 
After quenching and collection, droplets were coalesced by adding 50-µL 1H,1H,2H,2H-
perfluoro-1-octanol (Sigma-Aldrich, St. Louis, MO). Aqueous and oil phases were separated by 
centrifugation at 8000 rpm for 1 min at room temperature in a tabletop microcentrifuge (Centrifuge 
5418, Eppendorf, Hauppauge, NY). RNase A (10 mg/mL, Sigma-Aldrich, St. Louis, MO) and 
Proteinase K (10 mg/mL, ThermoFisher Scientific, Grand Island, NY) were added consecutively 
to the aqueous phase of both on- and off-chip processed samples to degrade RNA and proteins by 
incubating at 65 °C for 1 hour and 2 hours, respectively. The aqueous phases were then collected 
into clean tubes and DNA purified using a QIAquick PCR purification kit (Qiagen). The 
concentration of purified DNA was determined using the Qubit dsDNA assay (ThermoFisher 
Scientific, Grand Island, NY). The size distribution of the fragmented chromatin (nucleosomal 
DNA) was characterized using a Bioanalyzer (Agilent). All samples were diluted to or below 500 
pg/µL consistent with Bioanalyzer sample submission requirements. The percentage of 




Library preparation, sequencing, and bioinformatic analysis 
For PCR-free library preparation, purified DNA was loaded into 1.5% agarose gel and was 
separated at 110V for 1 h. The mononucleosomal DNA (~147 bp) was excised from the gel and 
purified using the Qiagen gel extraction kit. DNA concentration was determined by the Qubit 
dsDNA assay, and 1 µg DNA was used for library preparation using the Illumina TruSeq® DNA 
PCR-Free Sample Preparation kit with a slight modification. DNA was purified using 1.8x 
(volumetric ratio to each library) Agencourt Ampure XP beads (Beckman Coulter, Inc.) after the 
end repair step, and the final library was purified using 0.55x Agencourt Ampure XP beads.  
For PCR-based library preparation, 10 ng DNA was used with the NuGEN Ovation 
Ultralow library system V2 (San Carlos, CA). DNA was end-repaired and ligated following 
manufacturer instructions. After the ligation reaction, the 200-300 bp range of DNA was collected 
by the Agencourt RNAClean XP beads and amplified by PCR. The amplified library was purified, 
and the size distribution of library DNA determined by the Fragment Analyzer (Advanced 
Analytical Technologies, Inc.) and the concentration determined by the Qubit dsDNA assay. Four 
indexed libraries were pooled and sequenced 51 bp from both ends in 4 lanes of Hiseq4000 
(Illumina Inc.) in the Mayo Clinic Center for Individualized Medicine Medical Genomics Facility. 
Reads were aligned to the hg19 genome assembly using BWA and visualized using 
Integrative Genomics Browser (IGV).51 Nucleosome peaks were identified and analyzed by 
Dynamic Analysis of Nucleosome Position and Occupancy by Sequencing (DANPOS) as 
described previously.52,53 
 
Results and Discussion 
Overview of the droplet microfluidic nucleosome preparation workflow 
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We report a droplet microfluidic device that enables automated, enzymatic chromatin 
processing that is amenable to variable-sized, whole cell input material, workflow shown in Figure 
3-2a. Unfixed Jurkat cells are combined with a stream of combined lysis/digestion buffer 
immediately before being encapsulated into aqueous droplets at a T-junction geometry.54 All 
solution flows were controlled by syringe pumps. The flow rates of cell and lysis digestion buffer 
were the same, and a higher oil flow rate allowed segmentation (Figure 3-2b and Figure 3-3). The 
tube delivering cells onto the device was pre-treated with Pluronic F-127 to reduce cells sticking 
to the tube.55 A short serpentine mixing element was incorporated immediately after droplet 
formation to facilitate rapid mixing of cells, detergent and MNase solutions. Incubation time for 
cell lysis and chromatin digestion was achieved by a series of delay channels (Figure 3-4), with 
the number of delay channels increasing for longer incubation times. MNase is a Ca2+-dependent 
enzyme, so the digestion reaction was quenched by picoinjecting45 an EDTA buffer into passing 
droplets (Figure 3-5). A saltwater-filled electrode was used to supply an AC electric field that 
transiently destabilized the droplet interface to allow injection of this quenching buffer. Finally, 
processed droplets were collected in a 1.5-mL centrifuge tube for characterization of the resulting 
chromatin. The complete experimental setup, including syringe pumps and the stereoscope, is 














Figure 3-2 (a) Schematic of the automated, droplet-based microfluidic nucleosome preparation 
process. The whole procedure contains three steps: (i) loading cells, detergent, and MNase to the 
device for droplet generation, (ii) droplets traveling down the delay channel for chromatin 
digestion to complete, (iii) injecting EDTA solution to droplets to quench the enzymatic processing 
and collect products. (b) The 8-row device. Delay line and electrolyte channels are highlighted 












Figure 3-3 Time sequence of droplet formation in the developed enzymatic chromatin digestion 
device. Jurkat cell suspension contained 125,000 cells in 30-µL volume. The black arrows 
indicated the liquid flow directions, and the red arrows indicated the formation of one specific 


















Figure 3-4 Illustration of droplets travelling across the series of delay channels. (a) Droplets 
entering the delay channel after generation. (b) Droplets travelling through the last constriction 












Figure 3-5 Time sequence of EDTA buffer injection to quench the enzymatic digestion reaction 
in passing droplets. The black arrows indicated the liquid flow directions. The electrode pairs 
supplied by salt water was labeld as “ground” and “high voltage”, respectively. 
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Multifaceted characterization of on-chip digestion efficiency  
Common to standard benchtop chromatin processing is the optimization of MNase 
concentration and digestion time. For many applications, including nucleosome positioning assay 
and ChIP, DNA fragments approximating the size of DNA associated with a single nucleosome 
are most ideal, with ≥80% mononucleosomal DNA being an empirical benchmark.56 To identify 
optimal conditions for on-chip digestion, we first titrated the concentration of MNase with a fixed 
delay/incubation time in the droplet microfluidic device and performed fragment analysis on 
purified DNA from the resulting digested chromatin. In parallel with on-chip experiments, 
identical digestion conditions were probed in an off-chip control experiment performed manually 
in Eppendorf tubes. Using a device that allowed for approximately 210 s of incubation, MNase 
concentrations varying from 5.3 to 266.7 GU/L were introduced to an input of 125,000 Jurkat 
cells, with results shown in Figure 3-6. As expected, the amount of DNA fragments corresponding 
to the size of DNA associated with a single nucleosome (~150 bp) increased as the concentration 
of MNase was increased (Figure 3-6a). At the lowest MNase concentration, the chromatin was 
under-digested, with purified DNA fragment bands clearly representing the length of DNA 
associated with mono-, di-, and tri-nucleosomes, in addition to much larger chromatin fragments 
(Figure 3-6b, the black trace). As the concentration of MNase was increased, large fragments of 
chromatin were further digested to yield predominantly mononucleosomes, with >80% integrated 
intensity being present in the mononucleosomal DNA band at concentrations equal or greater than 
133.3 GU/L. Further increasing the MNase concentration did not result in appreciable gains in 
mononucleosome yield (Figure 3-6c). Importantly, off-chip controls showed an identical trend 
towards higher mononucleosome yield with increasing enzyme concentration (Figure 3-7), 
indicating that there was no bias or artifacts introduced in droplet microfluidic chromatin 
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processing. While not significantly different across all conditions per student t-test, the on-chip 
chromatin processing gave equivalent if not improved mononucleosome yield compared with off-
chip controls. Closer inspection of the DNA fragment analysis for the two highest MNase 
concentrations showed further digestion to yield DNA sizes smaller than the typical 
mononucleosome. The slightly over-digested mononucleosomal DNA is desirable for the 
nucleosomal positioning assays described later in this manuscript but may not be optimal for other 
applications. However, since a 10-fold range of MNase concentration (i.e., from 26.7 to 266.7 
GU/L) generated mononucleosomes in the tested conditions, our method permits the selection of 
the MNase concentration most suitable for any particular application. In this study, given the desire 
to minimize reagent consumption, the concentration of 133.3 GU/µL was selected for further 












Figure 3-6 Characterization of chromatin digestion efficiency with different MNase 
concentrations. (a) Electropherogram of digested chromosomal DNA collected from cells 
processed in the droplet microfluidic devices (on-chip, lane 1-4) and 1.5-mL microcentrifuge tubes 
(off-chip, lane 5-8). MNase concentrations are listed on the bottom. (b) Electrophoretic band 
intensity profiles of on-chip samples. The peaks at 35 bp and 10380 bp are internal standards. (c) 




After determining a suitable MNase concentration, we turned to optimization of incubation 
time. Shorter incubation periods are not only advantageous from a time perspective, but shorter 
delays also reduce device footprint and the potential for complications of backpressure or 
fabrication. Devices having four different incubation times (45, 90, 210, and 305 s) were designed 
and fabricated using the aforementioned protocol. A cell input of 125,000 Jurkat cells were 
introduced to the device and combined with 133.3 GU/µL MNase in the lysis/digestion buffer, and 
Figure 3-7 Characterization of chromatin digestion efficiency in off-chip control experiments with 
different MNase concentrations with a common incubation time of 3.5 minutes. Electrophoretic 
fragment analysis shows increasing mononucleosome yields with higher MNase concentrations. 
The peaks at 35 bp and 10380 bp represent internal standards. 
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DNA from the resulting chromatin was analyzed for fragment size distribution (Figure 3-8). At 
the shortest incubation time (45 s), bands for mono-, di-, and tri-nucleosomal DNA were apparent, 
in addition to larger fragments (Figure 3-8a). However, longer delay times showed increasing 
mononucleosome yield (Figure 3-8b).  Again, it is important to note that the droplet microfluidic 
device was equivalent or superior to the off-chip control experiments (Figure 3-8b, 9 and 10)—
particularly at shorter incubation times as the mononucleosome yield from samples processed on 
chip for 45 s was significantly higher from that of off chip (p < 0.05). This observation might be 
explained by the efficient mixing within droplet due to counter-rotating recirculation zones.29 To 
balance the incubation time with mononucleosome yield especially the desire to obtain more 
slightly over-digested mononucleosomes, the device design offering a delay time of 210 s was 
selected for subsequent experiments. 
 
 
Figure 3-8 Characterization of chromatin digestion efficiency with different lengths of delay time. 
(a) Electrophoretic band intensity profiles of on-chip samples. The peaks at 35 bp and 10380 bp 
represent internal standards. (b) Mononucleosome yields from all samples. Error bars are standard 









Figure 3-9 Characterization of chromatin digestion efficiency in off-chip control experiments with 
different incubation periods with a common MNase concentration of 133.3 GU/µL. 
Electrophoretic fragment analysis shows increasing mononucleosome yields at longer incubation 





Validation of flexible sample input 
To demonstrate flexibility in terms of cell input, we investigated the chromatin digestion 
efficiency using samples varying from 2,500 to 125,000 cells. Jurkat cell inputs were combined 
on-chip with 133.3 GU/L of MNase and allowed to be enzymatically digested for 210 s. For 
consistency, these variable cell numbers were suspended in a fixed volume of density-adjusted 
PBS buffer. Importantly, this fixed-volume approach holds over a large input range—until a large 
number of droplets would have more than a single cell per Poisson statistics. Furthermore, this 
protocol should be amenable to clinical samples where the cell number is not precisely known. 
DNA fragment analysis from the resulting chromatin revealed high (~80%) mononucleosome 
yields across all cell inputs, with differences found not to be significant via single factor ANOVA 
Figure 3-10 Gel image of digested chromosomal DNA collected from cells processed on chip 
(lane 1-4) and off chip (lane 5-8). The incubation periods are listed on the bottom. More DNA 




test (p > 0.05) (Figure 3-11a). Again, for all cell inputs, the mononucleosome yield was equivalent 
to or better than that observed in off-chip controls (Figure 3-11b, 12, and 13). Importantly, the 
mononucleosome yield obtained from the droplet microfluidic device is independent of cell input, 
and the resulting input material can be optimized for downstream applications, including ChIP and 
nucleosome positioning assays. It is also important to note that the minimum number of cells used 
in these studies is limited by the analytical characterization methods, such as the Bioanalyzer. Cells 
are encapsulated into droplets according to Poisson statistics and under our cell concentrations and 
oil and buffer flow rates cells are almost always incorporated at a single cell level (i.e. one cell per 
drop, with many empty drops, too). Therefore, cell digestion is almost always occurring at the 
single cell level and there is no reason to anticipate that this device could not be used in conjunction 
with single cell sequencing for single cell nucleosome positioning experiments. 
 
 
Figure 3-11 Validation of chromatin digestion with flexible cell inputs. (a) Electrophoretic band 
intensity profiles of on-chip samples. The peaks at 35 bp and 10380 bp are internal standards. (b) 








Figure 3-12 Characterization of chromatin digestion efficiency in off-chip control experiments 
with flexible cell inputs. The electrophoretic band intensity profiles of off chip samples confirmed 
the consistent efficiency in mononucleosome yields at the optimal conditions, i.e. a common 
MNase concentration of 133.3 GU/L and an incubation time of 210 s. The peaks at 35 bp and 




Nucleosome positioning analysis enabled by droplet microfluidically-prepared 
mononucleosomal DNA  
Fragment analysis suggested that DNA of appropriate length and quality was produced by 
the droplet microfluidic MNase-digestion device; however, the ultimate validation of the resulting 
DNA for epigenetic analysis was further demonstrated by nucleosome positioning analysis. To 
ensure enough input DNA material for sequencing, the total amount of Jurkat cells for each 
separate digestion was increased to 500,000 (suspended in 50 L of buffer) so that >1 g of DNA 
could be collected. The digestion efficiency confirmed again this device’s capability of handling 
flexible sized samples from perspectives of both variable volumes and cell concentrations (Figure 
B-1). Libraries for sequencing were then prepared using both PCR-free and PCR-amplified library 
generation protocols. The PCR-free library procedure has the advantage that it eliminates potential 
Figure 3-13 The gel image of digested chromosomal DNA with flexible cell inputs processed on 
chip (lane 1-4) and off chip (lane 5-8). Starting input cell numbers were listed on the bottom. 
Notice more DNA fragments smaller than 150 bp were presented in on-chip processed samples, 
suggesting overdigestion that is desired in precise mapping of nucleosome positions. 
72 
 
biases from the PCR procedure,57-59 whereas the PCR-amplified procedure is important to test for 
future applications of low input nucleosome positioning. In parallel, off-chip-prepared 
mononucleosomal DNA was also prepared into libraries via PCR and PCR-free. Following library 
preparation, samples were analyzed via next-generation sequencing on an Illumina Hi-Seq 4000 
platform with one sample run per lane to obtain sufficient depth for high-resolution determination 
of nucleosome positioning and total nucleosome count. 
PCR-free libraries resulted in 240 ± 6 million (mean ± standard deviation) uniquely 
mapped reads per sample (on-chip: 236 and 245 million; off-chip: 245 and 234 million). After the 
removal of duplicate reads, PCR-amplified libraries generated 168 ± 4 million uniquely mapped 
reads per sample (on-chip: 162 and 171 million; off-chip: 168 and 170 million). The resulting 
nucleosome positioning analyses are shown in Figure 3-14 and Figure 3-15, allowing comparison 
of on-chip and off- chip chromatin digestion, as well as PCR-free and PCR-amplified library 
preparation. IGV traces of genomic regions for the constitutively expressed genes EIF1 
(eukaryotic translation initiation factor 1) and FH (fumarate hydratase) consistently show phased 
and well-positioned nucleosomes flanking the NFR associated with each gene’s transcription start 
site (TSS) (Figure 3-14). This is consistent with these genes being under active transcriptional 
regulation. By comparison, NFRs are not observed at the TSS for the genes GFAP (glial fibrillary 
acidic protein) and TH (tyrosine hydroxylase), which are developmentally repressed in T cells. 
Further genome-wide aggregation analysis revealed remarkably well-conserved nucleosome 
positioning flanking the TSSs of all genes (Figure 3-15), with at least 5 well-positioned 
nucleosomes with little fuzziness flanking the TSS over a genomic region of ±1.5 kB. This 
observation is consistent with literature precedent using bulk-prepared nucleosomal DNA.2, 9 
Importantly, mononucleosomal DNA from both the microfluidically prepared and manually 
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prepared chromatin yielded highly similar numbers of sequencing reads and indistinguishable 
patterns of nucleosome positioning. This indicates an efficacy in using the droplet microfluidic 
device to generate qualified mononucleosomes for next-generation sequencing compared to 
traditional, manual processing. 
As a final comparative metric, Figure 3-16 shows that the number of called nucleosomes 
is nearly identical for on- and off-chip DNA and libraries prepared with and without PCR, with all 
sample preparation methods yielding approximately 15 million nucleosomes, i.e., the number 
expected based on the size of the human genome (approximately 3 billion bp) and the average size 
of nucleosomal plus linker DNA (200 bp)60. Furthermore, we found that the proportion of static 
plus partially overlapping nucleosomes in any two replicate samples (on- vs off-chip and PCR-
free vs. PCR-amplified) averaged to be more than 96% (Table 3-1). Taken together, these genome-
wide analyses demonstrate high reproducibility and identical performance of the droplet 
microfluidic device compared to manual processing in a tube. Additionally, PCR-free samples 
showed similar peak reads and distribution as those amplified by PCR, although PCR-amplified 
samples generated fewer useable reads and resulted in somewhat less well-defined nucleosome 
positions (Figures 3-14 and 15). However, the potential bias from PCR was still small, broadening 
the potential scope of application to smaller cell inputs. Overall, we robustly demonstrated that 
this droplet microfluidic nucleosome preparation strategy could provide effective samples for 
nucleosome positioning assays (MNase-seq) starting directly from cells, but with significant 



















Figure 3-14 Nucleosome profiles exemplified by four loci. Cells were digested by droplet 
microfluidic devices (“on”) and in tubes (“off”), and the libraries were constructed with (“PCR”, 
red) and without (“Free”, green) PCR amplification. Note NFRs and the well-positioned 
nucleosomes flanking them near the TSSs of the consitutively expressed genes EIF1 (positive 
strand) and FH (negative strand). NFRs are not present near the TSSs of the developmentally 









Figure 3-15 Normalized genome-wide nucleosome occupancy near TSSs in Jurkat cells processed 











Figure 3-16 Nucleosome counts of sequenced samples that were on-chip (solid color) and off-chip 
(dashed) processed. Two libraries were generated from each sample (two biological replicates for 
on-chip and off-chip processing respectively, labeled as R1 in red and R2 in green), one directly 
constructed without PCR amplification (“Free”) and the other with PCR amplification (“PCR”). 
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Table 3-1 Statistical comparisons between sequenced samples. 
Comparing Type Sample A Sample B Overlapping Peaks* 
 ID ID Sample A Sample B 
Biological 
replicates 
off 1-Free off 2-Free 97% 98% 
Biological 
replicates 
on 1-Free on 2-Free 97% 97% 
Biological 
replicates 
off 1-PCR off 2-PCR 98% 99% 
Biological 
replicates 
on 1-PCR on 2-PCR 98% 98% 
off vs. on off 1-Free on 1-Free 97% 98% 
off vs. on off 2-Free on 2-Free 97% 97% 
off vs. on off 1-PCR on 1-PCR 98% 99% 
off vs. on off 2-PCR on 2-PCR 98% 99% 
Free vs PCR off 1-Free off 1-PCR 99% 98% 
Free vs PCR on 1-Free on 1-PCR 98% 97% 
Free vs PCR on 2-Free off 2-PCR 99% 96% 
Free vs PCR on 2-Free on 2-PCR 99% 97% 
*  Static and partially overlapping 
 
Conclusion 
We have developed a droplet microfluidic device to enable automated, enzymatic 
chromatin processing starting with intact cells as input. Using Jurkat cells as a model system, we 
show that cells can be simultaneously lysed and chromatin digested using MNase. We optimized 
both enzyme concentration and delay/incubation time to maximize yield of mononucleosomal 
DNA above 80% to fulfill the sample requirements of many downstream epigenomic assays 
including nucleosome positioning assay and ChIP. We also demonstrated that the microfluidic 
method is insensitive to cell input, performing robustly over a range of 2,500-125,000 cells. 
Importantly, we found that the microfluidic device met or exceeded the performance of off-chip, 
bulk sample processing, as is conventional. We then utilized the collected mononucleosomal DNA 
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for nucleosome positioning analysis and found well-positioned nucleosomes in regions flanking 
TSSs of actively transcribed genes. We also found consistent nucleosome counts for on- and off-
chip-processed samples and good performance for libraries prepared using both PCR-free and 
PCR-amplified kits. The separate success of both low input sample processing and PCR-amplified 
library preparation suggests amenability to future studies of nucleosome positioning from samples 
having limited input material. Finally, the advantages of the droplet microfluidic device in terms 
of automation and potential for parallelization make this a promising technology for a range of 
epigenetic analyses that require controllable and reproducible chromatin digestion to provide input 
material as the first step in downstream assays. 
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Chapter 4 A Droplet Microfluidic Platform Automating Simultaneous Sample Preparation 
for Two Different Epigenomic Assays 
 
Abstract 
Accessible chromatin may represent critical regulatory regions for gene expression 
including promoters and enhancers and coincide with nucleosome-free or nucleosome-depleted 
regions. Probing chromatin accessibility thus reveals the available binding sites for transcriptional 
machinery molecules and potential active DNA and histone modification locations nearby, 
therefore helps elucidate the related epigenomic regulatory network. In this chapter, a droplet 
microfluidic device is described in detail that can generate two samples for two epigenomic assays 
that provide complimentary information (MNase-based accessibility assay followed by 
sequencing, or MBA-seq, and MNase-seq. Samples for these two assays were referred to as MBA 
and MNase samples or DNA, respectively) from the same cell input sample with the same enzyme. 
Quality control experiments proved that the MBA samples prepared by the microfluidic device did 
enrich linker DNA that are related to open chromatin as the fold change of known regulatory 
sequences relative to reference gene region surpassed empirical threshold, and the MNase samples 
did get digested to mostly of mononucleosome size. Paired MBA and MNase samples were then 
prepared from K-562 cell lines and patient buffy coat to be sequenced and compared with existent 
methods for a final validation of the developed strategy for simultaneous investigation of open 





Eukaryotic chromatin is a packed format of nucleosomes, whose dynamic positioning and 
occupancy have regulatory function affecting chromatin-based biological processes including 
transcription, DNA repair and replication.1 Usually, nucleosomes tend to contain histone variants 
and active histone marks such as H3K4me1/2 and H3K27ac to obtain destabilization and become 
evicted at cis-regulatory elements including active promoters, enhancers, and silencers.2-4  Thus, 
these regulatory regions commonly coincide with nucleosome-free or depleted regions (NFR or 
NDR, respectively) to ensure the accessibility of DNA to non-histone proteins including the 
binding of transcriptional machineries and chromatin regulators.3, 5, 6 Probing accessible DNA or 
nucleosome-free DNA therefore provides valuable insights in the localization of gene regulatory 
regions. Additionally, the crosscheck of assessible DNA regions with nucleosome positioning 
patterns also benefits the identification of boundary nucleosomes of open chromatin which are 
usually the targets of active or poised histone marks.7 Thus, assessing accessible DNA or open 
chromatin plays a crucial role in elucidating genome-wide dynamics of epigenomic regulation of 
nucleosome occupancy and chromatin remodeling during important biological processes like gene 
expression, cell differentiation, and disease development.8-12 
Common accessible chromatin investigating assays work by applying chromatin to 
controlled enzyme or chemical treatment to isolate the accessible DNA as these regions are more 
fragile to the enzymatic or chemical attack without the protection of canonical nucleosome 
structures. For example, DNase-seq utilizes the endonuclease DNase I to selectively digest non-
occluded DNA and effectively characterizes DNase I hypersensitive sites that are historically all 
different types of regulatory regions.13-16 ATAC-seq, an assay for transposase-accessible 
chromatin using sequencing, utilizes hyperactive Tn5 transposase to fragment and tag the genome 
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with sequencing adaptors simultaneously to enable fast genome-wide mapping of active regulatory 
elements, nucleosome positioning, and chromatin accessibility simultaneously.17-21 FAIRE-seq, or 
formaldehyde-assisted isolation of regulatory elements followed by sequencing, uses 
formaldehyde to crosslink DNA with proteins prior to sonication-induced chromatin shearing and 
enrich nucleosome-depleted DNA that are of reduced crosslinking into aqueous phase by phenol-
chloroform extraction before sequencing.22 Therefore, FAIRE-seq serves as another alternative to 
DNase-seq and ATAC-seq without relying on any enzymatic digestion.23  
Although these powerful epigenomic assays have revealed valuable information on open 
chromatin, they have their own limitations. DNase-seq can suffer from DNase I’s cleavage bias 
leading to inaccurate transcription factor footprinting.15 ATAC-seq may be able to map 
nucleosomes, but only limited to those in close proximity to accessible sites.17 ATAC-seq also 
requires careful matching of cell numbers to Tn5 amount.  FAIRE-seq doesn’t have enzyme 
digestion bias, but can be affected by fixing condition and efficiency, and it has lower resolution 
identifying promoters compared to DNase-seq.24 Additionally, FAIRE-seq suffers from its lower 
signal-to-noise ratio compared to other chromatin accessibility assays, biasing the results towards 
only strong signals.25 Moreover, they all use different enzymes or chemicals from MNase, making 
it difficult to carry out one accessible DNA assay and the nucleosome positioning assay (MNase-
seq) simultaneously on the same sample under similar conditions besides additional reagent cost. 
Hence, it will be beneficial and interesting to develop a method that can inspect accessible regions 
as well as is compatible with nucleosome positioning assay via MNase-seq.  
 In this chapter, sample preparation for a new assay, MNase-based accessibility assay 
followed by sequencing or MBA-seq that was initially developed at Mayo Clinic, Rochester, was 
automated using droplet microfluidics and was paired with mononucleosome preparation for 
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MNase-seq. The developed platform delivered two processed samples, MBA and MNase samples, 
at the same time with the same cell input allowing the probing of accessible DNA regions and 
nucleosome positioning from the same source, thus reducing data incompatibility from 
heterogeneity of sample replicates. By manipulating droplets in passive mode on the device, the 
loaded cell suspension was aliquoted into two directions, one being digested by MNase for a short 
period of time, the other longer. After collection of digested chromatin, sample purification and 
quality control by qPCR were operated to ensure the enrichment of open chromatin on the MBA 
side and mononucleosomal DNA on the MNase side. An optimal design of microfluidic device 
was selected based on quality control results for the production of paired MBA-/MNase-seq 
samples from K-562 cells and human buffy coat for the subsequent sequencing as a final approval 
of the developed droplet microfluidic platform.  
 
Materials and Methods 
Microfluidic device fabrication 
Microfluidic devices were generated using standard photolithography and soft lithography 
methods with details described in Chapter 2 and the brief summary in Chapter 3. Photolithography 
masks for all tested devices were designed in AutoCAD (Schematic for the optimal device’s design 
and naming rule were shown in Figure 4-1, selected representative of other designs and naming 
rules listed in Figure A-2 in Appendix A). Briefly, SU8 2025 (MicroChem Corp, Westborough, 
MA) was first spin coated (PWM 32, Headway Research, Inc) onto the silicon wafer at 2000 rpm 
for 30 seconds to give a 40-µm thick layer. After soft baking, the resist layer was exposed to a UV 
lamp (Optical Associates, Incorporated) through the first-layer photomask. After post-exposure 
baking, the patterned wafer was developed in propylene glycol monomethyl ether acetate 
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(PGMEA) (Sigma-Aldrich, St. Louis, MO) and dried under nitrogen. SU8 2050 was then spin 
coated onto the patterned wafer at 1150 rpm for 30 seconds to give a 160-µm thick layer. After 
soft baking, the resist was exposed to UV through the second-layer photomask and then developed 
as described above. After that, the PDMS base and elastomer curing agent (Momentive RTV 615 
kit, R.S. Hughes, Carol Stream, IL) were mixed at a mass ratio of 10:1 and degassed under vacuum 
before poured over the master. After curing and peeled off from the master, the PDMS replica was 
punched for tubing inserting holes with blunt-tip biopsy needles (18 gauge for inlets, 20 gauge for 
the outlet and electrolyte inlets). The device replicas were then sonicated in water for 5 min and 
dried with nitrogen to remove any PDMS debris. In parallel, a base layer was created on a glass 
slide by spinning a degassed, 10:1 PDMS base:elastomer mixture onto the glass microscope slide. 
This base layer was partially cured for 8 min before the microfluidic replica was placed on top 




Microfluidic device operation 
Solutions were delivered to the device through 24-gauge PTFE tubing (Cole-Parmer, 
Vernon Hills, IL) controlled by syringe pumps (Pump 11 Pico Plus Elite, Harvard Apparatus). The 
immiscible oil phase was the fluorinated oil Novec 7500 (3M, St. Paul, MN) with 2% (w/w) 
perfluoropolyether polyethylene glycol block co-polymer surfactant (RAN Biotechnologies, Inc. 
Beverly, MA). The tubing to deliver cells to the device was treated with 1% (w/v) Pluronic F127 
Figure 4-1 Schematic of the photomask design of the selected, optimal device “6RASD” for 
MBA/MNase-seq sample preparation, the name standing for “6+1 rows of delay channels, 6 
rows for MNase side, 1 row for MBA side, aliquoting right after droplet generation, ‘single 
layer’ or thin, 40-µm delay for MBA side, ‘dual layer’ or thick, 160-µm delay for MNase side”. 
Other designs such as “6RABD” had similar structures but with both sides being dual layered 
(160-µm) delay channels. The red parts were the first layer of 40-µm thickness, and the black 
part the second layer of 160-µm thickness. The two layers were printed on two individual masks. 
They should be aligned to ensure the connection of the channels (shown as the overlap between 
the red and black). The zoom-in insertion showed the design for droplet aliquoting to the MBA 
and MNase sides, respectively. The scale bar in the zoom-in insertion was 500 µm. 
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(Sigma-Aldrich, St. Louis, MO)-containing PBS solution overnight and prefilled with PBS buffer. 
Two sets of electrolyte channels for the two injection sites on the microfluidic device for MBA 
and MNase samples respectively were all filled with a 3M sodium chloride solution. For each set, 
two clamps from electrodes of an in-house built DC-AC converter (12V DC input, 0-360V AC at 
36 kHz as output), which was connected to a power supply (DC regulated power supply, TENMA 
T2-6628), were connected to the syringe needles supplying the electrolyte channels to form a 
complete circuit for the AC electric field.  
Prior to experiments, microfluidic devices were treated with Aquapel (Pittsburgh Glass 
Works, Pittsburgh, PA) as described previously26 to give a hydrophobic coating throughout sample 
processing. Optiprep (Sigma-Aldrich, St. Louis, MO) was added to PBS buffer to obtain a final 
density of 1.07 g/mL at a 21.9% (v/v) concentration. Cells were resuspended in this density-
adjusted PBS buffer to reduce clumping and settling in the tubing. Cell suspensions were drawn 
into the pre-treated tubing separated from the pre-filled buffer by a plug of air. Lysis buffer (pH 
7.9) contained 10 mM HEPES, 1.5 mM magnesium chloride (MgCl2), 10 mM potassium chloride 
(KCl), and 0.5% (w/v) IGEPAL-CA630 (Sigma-Aldrich, St. Louis, MO). Digestion buffer (pH 
7.5) contained 20 mM Trizma hydrochloride (Tris-HCl), 15 mM sodium chloride (NaCl), 60 mM 
KCl, 5 mM calcium chloride (CaCl2), 0.15 mM spermine, and 0.5 mM spermidine. Quenching 
buffer (pH 8) contained 100 mM Tris-HCl, 20 mM ethylenediaminetetraacetic acid (EDTA), 200 
mM NaCl, 2% Triton-X 100, and 0.2% sodium dodecyl sulfate (SDS). Elution buffer (pH 8) 
contained 20 mM Tris-HCl, 20 mM EDTA, 300 mM NaCl, and 2% SDS. The combined lysis-
digestion buffer was prepared by mixing 30 µL MNase (2000 GU/µL; New England Biolabs, 
Ipswich, MA), 120 µL digestion buffer, and 300 µL lysis buffer.  
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Flow rates of oil (6 µL/min), cell suspension (2 µL/min), lysis-digestion reagent (2 µL/min), 
quenching buffer (4 µL/min), and elution buffer (4 µL/min) were optimized to ensure that droplets 
with appropriate size were generated, droplets travelled across the delay channels at both directions 
for appropriate time to allow limited or thorough MNase digestion respectively, and quenching 
buffer and elution buffer were injected into every droplet at both MBA and MNase injection sites. 
Droplets were collected via two 30-gauge PTFE tubing (Cole-Parmer) into two 1.5-mL tubes 
(Eppendorf DNA LoBind, Fisher Scientific, Waltham, MA) respectively. Device operation was 
visualized using a high-speed camera (Phantom Miro Ex2) mounted onto either a stereoscope 
(Leica M80) or microscope (Leica DMi8). 
 
Cell culture, buffy coat extraction, and microfluidic sample preparation 
K-562 chronic myelogenous leukemia lymphoblast cells (ATCC® CCL­243™, American 
Type Culture Collection, Manassas, VA) were cultured at 37°C with 5% CO2 in the vendor 
recommended media (ATCC-formulated Iscove’s Modified Dulbecco’s Medium, Catalog No. 30-
2005, supplemented with 10% v/v fetal bovine serum). The cells suspended in 10 mL medium 
were fixed with 625-µL 16% formaldehyde (Methanol-free, Pierce™, Catalog No. 28906, 
ThermoFisher Scientific) for 5 min at room temperature. Fixation reaction was quenched by 
adding 500-µL 2.5M glycine solution and incubated for 5 min at room temperature. The cells were 
pelleted at 800×g for 5 min at 4°C, washed with cold PBS buffer, and resuspended into the density-
adjusted PBS buffer to a defined concentration, as described below. After resuspension, cells were 
stored on ice until chromatin digestion. Digestion experiments of K-562 cells were carried out with 




Buffy coat (white blood cells and platelets, the blood components other than red blood cells 
or plasma) was extracted from whole blood samples of healthy donators via venipuncture and 
collected in anti-coagulant containing blood collection tubes (K2EDTA tubes with purple caps) by 
the Department of Emergency Medicine of the University of Michigan Taubman Center and 
Michigan Center for Integrative Research in Critical Care (MCIRCC). Blood samples were then 
aspirated into a 50-mL conical tube and treated with ACK lysing buffer (Catalog No. A1049201, 
Thermo Fisher Scientific) based on the manufacturer’s recommended protocol. Briefly, 1-mL 
whole blood was mixed with 12-mL ACK lysing buffer and incubated at room temperature for 5 
minutes. Buffy coat was collected by centrifugation at 300 x g for 5 minutes at room temperature 
and the removal of supernatant. Additional 3-mL ACK lysing buffer could be added to the buffy 
coat for another 2-minute incubation if significant numbers of red blood cells remained on the top. 
After centrifugation and supernatant aspiration, buffy coat cells washed with 5-mL cold PBS 
buffer and centrifuged for the pellet. The washed buffy coat was then resuspended in a specific 
volume of density-adjusted PBS buffer (see Chapter 3 for detailed recipe) for desired cell 
concentration. Digestion experiments of buffy coat were carried out with 60 to 100 µL volumes of 
cell suspension at a density of 10 million cells per mL, unless otherwise stated. The usage of human 
subject materials for this research was approved by the Health Sciences and Behavioral Sciences 
Institutional Review Board (IRB-HSBS) on the University of Michigan – Ann Arbor Campus.  
 
Characterization of fragmented chromatin 
Collected droplets from both directions were coalesced by adding 50-µL 1H,1H,2H,2H-
perfluoro-1-octanol (Sigma-Aldrich, St. Louis, MO). Aqueous and oil phases were separated by 
centrifugation at 8000 rpm for 1 min at room temperature in a tabletop microcentrifuge (Centrifuge 
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5418, Eppendorf, Hauppauge, NY). RNase A (10 mg/mL, Sigma-Aldrich, St. Louis, MO) was 
added to the aqueous phases of both MBA and MNase samples to degrade RNA by incubating at 
65 °C for 1 hour. Proteinase K (10 mg/mL, ThermoFisher Scientific, Grand Island, NY) was added 
consecutively to the aqueous phases of both MBA and MNase samples to degrade proteins by 
incubating at 65 °C for 2 hours. The samples were maintained on the hotplate at 65 °C for another 
hour to ensure full reverse-crosslinking of DNA and protein residues. The aqueous phases were 
then collected into clean tubes. DNA for MNase-seq were purified using a QIAquick PCR 
purification kit (Qiagen), and DNA for MBA-seq were purified using a QIAquick Nucleotide 
Removal kit (Qiagen). The concentration of purified DNA was determined using the Qubit dsDNA 
assay (ThermoFisher Scientific, Grand Island, NY). The size distribution of the DNA purified from 
fragmented chromatin (both limited digested DNA containing nucleosome-free regions for MBA-
seq, and mononucleosomal DNA for MNase-seq) was characterized using a Bioanalyzer (Agilent). 
All samples were diluted to or below 500 pg/µL consistent with Bioanalyzer sample submission 
requirements. The percentage of mononucleosomal DNA in the total DNA was obtained from the 
Bioanalyzer software.  
 
Size selection of linker DNA 
QIAquick purified DNA from MBA samples were first incubated with 2.5× volumes 
(compared to DNA solution volume) of room-temperature Agencourt Ampure XP beads 
(Beckman Coulter, Inc.) for 15 minutes to allow high bp DNA to bind with the beads 
(approximately > 100 bp). The linker DNA was collected by centrifuging the beads and using a 
magnet to attract the beads for 5 min and taking the suparnant. The volume of the supernatant was 
made up to 400 µL by adding EB buffer from QIAgen PCR purification kit (notice that this is EB 
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buffer, not the in-house made elution buffer described in section “Microfluidic device operation”), 
and the solution was mixed with 6-µL glycogen (Catalog No. R0561, ThermoFisher Scientific), 
8-µL 5M NaCl, and 800-µL 100% cold ethanol freshly taken from -20 °C freezer and incubated 
overnight. The pellet of glycogen containing linker DNA was collected by centrifugation of the 
mixture at maximum spin rate for 13 minutes at 4 °C and pouring out the supernatant. After 
washing the pellet with 700-µL 70% ethanol taken from -20 °C freezer and centrifuging at max 
spin rate for 5 minutes at 4 °C, the solution was pipetted out carefully to leave the pellet, which 
was dried for 5 minutes at room temperature by opening the tube lid and exposing to air. The first-
round size selected linker DNA was eluted with 10.5-µL EB buffer from QIAgen by dissolving 
the glycogen pellet into the EB buffer, incubating for 5 minutes, spinning briefly, and pipetting 
out 10-µL aqueous phase into a clean DNA Lobind tube after putting the solution onto a magnetic 
stand to avoid leftover beads’ contamination. 
The purified DNA was then constructed into Illumina compatible libraries with ThruPLEX 
DNA-seq kit (Rubicon Genomics) based on the manufacturer’s recommended protocol with slight 
modifications: in the third section of “Library Amplification Reaction”, the last step of “Addition 
of Indexes” was shortened to 20 s, and the last step in “Library Amplification” was shortened to 
5-10 s to selectively amplify the 30-100 bp linker DNA. Libraries were then purified with Ampure 
XP beads following Rubicon’s recommended protocol.  After collecting the 100-300 bp bands of 
the 2% agarose gel of the libraries, the adaptor ligated linker DNA were extracted with QIAgen’s 
MinElute gel extraction kit (Qiagen) and eluted to 15-µL EB buffer. These linker DNA for MBA-
seq were ready for quality control. 
 
Quality control of collected MBA and MNase DNA  
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Two known accessible loci (CD47 enhancer and DZIP3) were used as positive targets to 
assess the enrichment of nucleosome-free, accessible regions of MBA samples. An inaccessible 
locus (C19 intergenic region27) was used as reference evaluating the digested chromatin’s 
background. Sequences of primer pairs for these three regions were listed in Table B-1 in 
APPENDIX B.  
Quantitative PCR reaction per well on the 384-well reaction plate (Applied Biosystems 
Catalog No. 4309848, Fisher Scientific) was set up according to the manufacturer’s recommended 
parameters. Briefly, for each target, 10-µL PowerUp™ SYBR™ Green master mix (Applied 
Biosystems Catalog No. A25776, Fisher Scientific) was mixed with 2-µL forward primer (5 µM) 
and 2-µL reverse primer (5 µM). Then 2 to 3 µL of DNA template was added to the mix depending 
on the DNA concentration to ensure appropriate amount of DNA was used. The volume was made 
up to 20 µL by adding appropriate volume of nuclease-free water. After setting up the PCR plate, 
the experiment was run on 7900HT Fast Real-Time PCR system (Applied Biosystems) with the 
standard parameter setup at the DNA sequencing core facility (University of Michigan). Fold 
change of positive loci (posi) between MBA DNA (BA) and MNase DNA (MN) was calculated 
using equation (4.1) to assess the efficiency of accessible region enrichment in the MBA DNA. 
𝑙𝑜𝑔2 𝑓𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 = 𝑐𝑡(𝐵𝐴,𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒) − 𝑐𝑡(𝐵𝐴,𝑝𝑜𝑠𝑖) − (𝑐𝑡(𝑀𝑁,𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒) −  𝑐𝑡(𝑀𝑁,𝑝𝑜𝑠𝑖))  (4.1) 
 
Results and Discussion 
Overview of the device operation 
The optimal droplet microfluidic device shown in Figure 4-1 automated sample processing 
for MBA-seq and MNase-seq from cell input directly allowing simultaneous investigation of 
nucleosome-free and -associated regions of the same sample for regulatory region localization and 
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nucleosome positioning mapping, respectively. Fixed K-562 cells were loaded to the device 
through the left inlet to be coflowed with lysis-digestion reagent containing MNase and 
encapsulated into droplets cutting by the oil flow (Figure 4-2a). The droplets were directed to two 
different delay channels at the intersection (Figure 4-2b), the upper one for MBA-seq sample 
preparation as the thinner and shorter (40-µm, 1 row) delay channel only allowed < 10 s of reaction 
time for MNase to attack the most fragile regions of cellular chromatin, i.e., accessible regions that 
were nucleosome-free, while the lower one for MNase-seq sample preparation as the thicker and 
longer delay channel allowed sufficient time (> 5 min) for MNase to thoroughly digest chromatin 
and produce (mono-)nucleosomal regions that were protected. At both directions picoinjectors 
were designed to inject elution buffer or quenching buffer to the droplets (Figure 4-2c and d). 
Elution buffer contained higher concentration of SDS, thus was supposed to completely stop any 
enzymatic activity of MNase to preserve the fragile accessible regions, which was significant in 
their enrichment.  
Figure 4-3 showed the droplets travelling in the delay channels with intact integrity. 
Depending on the difference in length and thickness between MBA and MNase delay channels as 
well as droplet size and the location of aliquoting site, the ratio of numbers of droplets aliquoted 
between the two directions and the corresponding delay times would be varied. For the optimal 
design shown here, approximately 60% of produced droplets were directed to the MBA side. 
Notice that due to the existence of empty droplets and the different digestion levels between MBA 
and MNase samples, the ratio of numbers of droplets aliquoted between the two assays did not 










Figure 4-2 The operation of key components of the MBA/MNase sample preparing device. (a) K-
562 cells (4 million per mL) encapsulated into droplets. (b) Droplets aliquoted into the two 
directions for MBA and MNase sample processing. The upper branch directed droplets to the (c) 
MBA injection site as the delay time was only < 10 seconds in the one-row, single-layered delay 
channel, while the lower branch directed droplets to the (d) MNase injection site as the delay time 
was > 5 minutes in the six-row, thicker delay channel. The black arrows indicated the flow 




 Chromatin Digestion Efficiency of Devices with Different Designs 
As being described above, the accessible regions are more fragile to MNase attack 
compared to nucleosomal regions, thus the delay time for MBA sample side needed to be 
controlled carefully to preserve as much nucleosome-free regions as possible to avoid targeted 
sample loss or region bias in the subsequent analysis. Therefore, multiple designs of droplet 
microfluidic devices were tested to ensure that both accessible regions and mononucleosomes were 
achieved from the on-chip processed samples. Two criteria were applied here to assess the quality 
of both DNA products, one is digestion level, the other is quantitative PCR on known accessible 
and nucleosomal regions.  
In terms of digestion level, MBA DNA is expected to have limited digestion, empirically 
with little (~ or < 20%) to no visible peak at mononucleosomal range (about < 250 bp, 
mononucleosome length with linker DNA length), while MNase DNA is expected to have 
mononucleosome as the main product. Figure 4-4 showed the box plots with data points of 
digestion levels in the form of mononucleosome yield of samples produced from different droplet 
Figure 4-3 (a) Droplets travelling across the third constriction site of the delay channel on the 
MBA side. (b) Droplets travelling across the last constriction site of the delay channel on the 
MNase side. The black arrows indicated the flow direction of the oil and the droplets. 
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microfluidic devices. MBA and MNase DNA were generated in pairs from the same device, i.e., 
“4R_BA” and “4R_MN” contained two pairs of MBA and MNase DNA generated from two cell 
input replicates loaded to two devices of the same design, respectively. Each pair of data points 
stood for one replicate. Notice that “6RASD_BA” had two data points “missing” compared to 
“6RASD_MN”, because those two data points did not have effective values as the 
mononucleosomal region contained little area and could not be extracted effectively from the 
Bioanalyzer electropherogram profiles, indicating very limited digestion which could be beneficial. 
Moreover, considering the less MNase digestion efficiency for nucleosome positioning assay of 
fixed cells compared to native cells empirically (see Chapter 3), ~ 70% mononucleosome yield 
could be qualified. Additionally, MNase digestion efficiency should also be balanced with device 
footprint, therefore the length of MNase side delay channel should not be unlimitedly elongated. 
With these factors taken into consideration, as well as experimental reproducibility and data 
outliers revealed by Figure 4-4, 6RABD and 6RASD had the most potential to generate qualified 





Quantitative PCR as Quality control of Droplet Microfluidic Produced Samples  
Digestion efficiency was validated among literature as a criterion for assessing digested 
chromatin samples’ efficacy for MNase-seq28, 29; however, it was not the case for accessibility 
assay, especially for a new protocol as MBA-seq. A more biologically relevant benchmark should 
Figure 4-4 Mononucleosome yield of MBA-seq (“BA”) and MNase-seq (“MN”) samples from 
different devices. “4R” had 4 rows of thick, 160-µm delay channels in total, aliquoting at the end 
of the first row. “6RABD” had 6+1 rows of delay channels, 6 rows for MNase side, 1 row for 
MBA side, aliquoting right after droplet generation, both sides contained “dual layer” or thick 
delays. “8RABD” had 8+1 rows of delay channels, 8 rows for MNase side, 1 row for MBA side, 
aliquoting right after droplet generation, both sides contained “dual layer” or thick delays. 
“6RASD” had 6+1 rows of delay channels, 6 rows for MNase side, 1 row for MBA side, aliquoting 
right after droplet generation, “single layer” or thin, 40-µm delay for MBA side, “dual layer” or 
thick, 160-µm delay for MNase side. 
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be evaluated to confirm whether accessible regions were enriched in MBA DNA compared to 
MNase DNA (the latter should contain little to no nucleosome-free, accessible regions). Therefore, 
qPCR on known accessible and inaccessible regions for fold change calculation was selected to 
serve as the biologically relevant quality control method. The two known loci used as positive 
targets that were supposed to be enriched in MBA DNA were one human CD47 enhancer and 
human DZIP3. CD47 is a cell surface glycoprotein that inhibits phagocytosis of cells expressing 
it via binding to its receptor on macrophages and other immune cells. Therefore, CD47 is 
overexpressed on cancer cells including K-562 cells to survive the guard from immune system and 
its enhancers are accessible to realize the upregulation.30  DZIP3 (DAZ interacting zinc finger 
protein 3) is broadly expressed among multiple tissues and the coded protein is involved in ligase 
activity, therefore it is considered housekeeping gene and should always be assessible. Meanwhile, 
an inaccessible region, C19 intergenic, was used as a reference region to normalize the fold of 
positive targets to. This region was discovered to be between two genes, containing a nucleosome 
structure that has no histone modifications, hence should only exist with significant amount in 
MNase DNA but little should be found in MBA DNA. Based on empirical observations from 
collaborators at Mayo Clinic, Rochester, fold change of positive locus normalized against 
reference locus in MBA DNA should be ~ 5 times of that in MNase DNA, i.e., the result of 
equation 4.1 (∆∆Ct) should be around or more than log25 or 2.32. 
With the expected results bared in mind, qPCR was carried out on amplified and size 
selected MBA DNA and paired MNase DNA. Results in Figure 4-5 revealed that except for the 
samples from the 8RABD device and one trial of device 6RABD, all samples showed fold change 
more than 5 on both positive targets, DZIP3 showing higher enrichment compared to CD47 
enhancer. The two designs that showed expected digestion patterns on both MBA and MNase 
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sides, 6RABD and 6RASD, delivered samples that had higher enrichment of DZIP3 compared to 
other trials and significant enrichment of CD47 enhancer across most trials. Considering the bigger 
absolute values of the fold change and the higher consistency among all trials, the device 6RASD 
was selected as the optimal device for biological replicate collection from K-562 cells and buffy 
coat from healthy humans for the subsequent experiments.  
 
 
K-562 Cells and Buffy Coat Processing for Sequencing 
Figure 4-5 Delta Delta Ct (∆∆Ct, or log2(fold change)) of samples produced from different 
devices. “CD47e” stood for the targeted region of CD47 enhancer, and “DZIP3” stood for the 
targeted region of DZIP3. 
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With an optimal design selected, samples from K-562 cells and buffy coat were processed 
under developed conditions and submitted to the collaborators for next-generation sequencing to 
obtain a final validation on the efficacy of the developed MBA-seq protocol and the applicability 
of the droplet microfluidic platform for simultaneous sample collection for nucleosome-free region 
identification and nucleosome positioning analysis. Figure 4-6 to 9 confirmed the consistent 
performance of the droplet microfluidic device on biological triplicates for both sample types. 
Enough DNA were collected on both sides among all replicates to ensure successful library 
construction (Figure 4-6 and 8). More importantly, limited digestion occurred on MBA DNA 
while the main product for MNase DNA were of mononucleosome size, indicating the high 
possibility of correct enrichment of nucleosome-free regions and mononucleosomal DNA, 
respectively (Figure 4-7 and 9, also see Figure B-2 to 5 in APPENDIX B for representative K-
562 cells and buffy coat digestion patterns characterized with Bioanalyzer). The success of 
processing buffy coat samples was particularly impactful as buffy coat is a great representative of 
clinical samples from whole blood, a common medical sample from patients. Buffy coat being 
successfully processed by the developed droplet microfluidic platform enhanced the potential of 
this automated platform to be involved in clinical studies and contribute to disease-related 
information discovery. 
One thing to be noticed was that, I started K-562 cell sample collection with 60 µL of cell 
suspension at a density of 4 million per mL for the first two replicates and increased the volume 
to 100 µL for the next four replicates to obtain enough MBA DNA for subsequent processing in 
order to ensure multiple trials can be operated on the same sample if necessary. Similar input 
increase also existed in buffy coat collection. As buffy coat content was not necessarily the same 
from different subjects, the final MBA and MNase DNA amount were uneasy to anticipate, 
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therefore I started with 100 µL of buffy coat suspension at a density of 4 million per mL and 
increased the cell density to 10 million per mL with the other three replicates to increase the final 
DNA amount. The DNA amount of these samples with smaller input sizes were corrected 
proportionally to match with the cell input of other replicates in the corresponding sample pools 
(K-562 and buffy coat, respectively), and the results were surprisingly consistent across all 
replicates: none of the corrected values were outliers based on the box plots’ interquartile ranges 
(outliers are the ones bigger than 1.5 × interquartile range above the third quartile or the ones 
smaller than 1.5 × interquartile range below the first quartile), nor were they away from the means 
by more than 2 times of the standard deviations. Hence, this observation shed light again on the 
promising feature of droplet microfluidic platform’s sample size flexibility: as long as the cell 
suspension density did not surpass the upper limit where every generated droplet would contain 
one cell averagely, the sample size of a droplet microfluidic device could be enlarged by increasing 
the volume so the platform was run for a longer time, or increasing the suspended cell density so 
more droplets would contain a cell, without affecting the processing performance on chip as long 
as the droplets were processed under the same condition on the same (designed) device. This 
feature can be very practical and user-friendly when such a droplet microfluidic platform is 
commercialized and applied to treat clinical samples where the sample sizes are more likely to 
vary among different sources, and it still allows the expected, consistent performance from an 













Figure 4-6 K-562 cell samples’ DNA content collected from both MBA (“BA”) and MNase 
(“MN”) sides. Six replicates were processed. The upper end of the box represented the third 
quartile of the data group, and the lower end representing the first quartile. The whiskers 
represented one time of the standard deviation away from the mean from both directions, with 
mean represented by the square inside the box. Maximum and minimum of the data group were 










Figure 4-7 K-562 cell samples’ mononucleosome (or area below the peak curve about < 250 bp) 
yields from both MBA (“BA”) and MNase (“MN”) sides. Six replicates were processed. The upper 
end of the box represented the third quartile of the data group, and the lower end representing the 
first quartile. The whiskers represented one time of the standard deviation away from the mean 
from both directions, with mean represented by the square inside the box. Maximum and minimum 










Figure 4-8 Buffy coat samples’ DNA content collected from both MBA (“BA”) and MNase 
(“MN”) sides. Four replicates were processed. The upper end of the box represented the third 
quartile of the data group, and the lower end representing the first quartile. The whiskers 
represented one time of the standard deviation away from the mean from both directions, with 
mean represented by the square inside the box. Maximum and minimum of the data group were 





In this chapter, a droplet microfluidic device automating sample preparation for both a 
newly developed, accessible DNA region assay and a well-established, MNase-seq assay was 
described. Digestion patterns and qPCR quality controls on known accessible, nucleosome-free 
regions confirmed the efficacy of using droplet microfluidic devices to deliver qualified fragment 
chromatin for the investigation of nucleosome-free, regulatory region and nucleosome positioning 
Figure 4-9 Buffy coat samples’ mononucleosome (or area below the peak curve about < 250 bp) 
yields from both MBA (“BA”) and MNase (“MN”) sides. Four replicates were processed. The 
upper end of the box represented the third quartile of the data group, and the lower end representing 
the first quartile. The whiskers represented one time of the standard deviation away from the mean 
from both directions, with mean represented by the square inside the box. Maximum and minimum 
of the data group were marked by asterisks above and below each box. 
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simultaneously from the same sample. Samples of a model cell line and samples of clinical 
significance were prepared with the optimal designed device for the ultimate validation by next-
generation sequencing. The development of this device and the future possibility of running 
multiple of them in parallel for high throughput sample processing provide a splendid potential for 
the discovery of crucial regulatory regions and related functions in medical-relevant samples, the 
identification of nucleosome-free regulatory regions’ interplay with nucleosomes, and the 
crosscheck of data reliability and overlay of multiple layers of epigenetic profiles from the two 
important epigenomic assays (MBA-seq and MNase-seq) that provide complimentary information 
with each other, and will promote the development of automated epigenetic methodology for the 
insight into the complex epigenetic regulating network of gene expression. 
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Chapter 5 Using Droplet Microfluidics for Automated Chromatin Immunoprecipitation 
 
Abstract 
The gold standard to probe histone modification marks as well as other DNA-binding 
proteins is a technique called chromatin immunoprecipitation (ChIP), commonly followed by next-
generation sequencing to complete the protocol of ChIP-seq. While powerful, traditional ChIP 
protocols require a large cellular input (106-107 cells), which limits their utility to study biopsies, 
rare cells such as cancer and stem cells, and to assess tumor heterogeneity. ChIP is also laborious, 
time-consuming, and highly user-dependent. To address these disadvantages, we proposed a 
droplet microfluidic strategy to automate from cell lysis to immunoprecipitation of interested 
marks. The resulting product was clean chromatin fragments ready for DNA extraction and 
analysis via qPCR or next generation sequencing. This proposed strategy will provide 
unprecedented opportunity to study epigenetic profiles of low-input to single-cell level samples, 
allowing both the assessment of cell heterogeneity within complex clinical samples and the 
application of cost-effective epigenetic testing to very small samples in individualized medicine 
settings directly at the point of care. This chapter first described the characterization and validation 
of ChIP efficiency using in-house conditions mimicking the procedure occurring on the 
microfluidic device, then showcased the results of on-chip ChIP trials. Future directions for 





 Histones are significant components of nucleosomes and chromatin, assisting in packaging 
6 billion bp of human DNA into a micron-sized nucleus structure.1 H2A, H2B, H3, and H4 are the 
four core histones that form the octamer wrapped by DNA sequences. They all have flexible N-
terminal tails, but also C-terminal tails of H2A, protruding outside the nucleosomes.2 Most regions 
on these tails are potential targets of a variety of chemical modifications including acetylation, 
methylation, phosphorylation, and others, which are one category of the most investigated 
epigenomic regulators.3 They are recognized by specific “reader” protein complexes to trigger 
subsequent processes and are discovered to be associated with the regulation of fundamental 
processes such as initiation of transcription, activation/repression of gene expression and 
regulatory regions, and remodeling of chromatin conformation, thus are crucial in cell 
development, aging, and carcinogenesis.4-6 For example, trimethylation of H3K4 (H3K4me3) has 
been commonly found at transcription start sites (TSSs) of actively transcribed genes and is 
discovered to improve transcription machinery recruitment7, respond to induce gene expression 
upon environmental cues8, and maintain transcription consistency9. Mono- and di-methylation on 
H3K4 (H3K4me1 and H3K4me2, respectively) are marks for enhancers to help establish de novo 
enhancers and poise them for activation.10, 11 Acetylation of H3K27 (H3K27ac), after established 
by histone acetyltransferase, is associated with enhancer activation to promote gene expression, 
and are often found overlapped with H3K4me1.12, 13 On the other hand, H3K27me3 and H3K9me2 
are associated with repressed gene expression.14-16 Additionally, it has been recognized that histone 
marks usually work in combination with each other and other epigenetic marks to form a regulating 
network.14, 17 Their deposition and removal from chromatin is part of the complicated interplay 
between epigenome and genome, necessitating the persistent efforts trying to comprehend the 
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locations and functions of histone modifications in different cell statuses such as healthy vs. 
diseased and among different cellular development stages to fully clarify their significance in 
epigenetics.18, 19  
Currently, the standard method to localize histone modifications is the protocol called chromatin 
immunoprecipitation (ChIP), frequently followed by next-generation sequencing (ChIP-seq).1 
ChIP-seq generally involves steps of shearing chromatin into mono- and di-nucleosome sizes 
(about 150-300 bp) by sonication and/or micrococcal nuclease, immunocapturing the modification 
of interest with specific antibodies, and purifying captured DNA for library preparation and 
sequencing.20-22 ChIP is an affinity-based assay, therefore it can selectively target other DNA-
binding proteins besides histones simply by using appropriate antibodies and chemically fixing 
chromatin with interacting proteins to preserve transient interaction prior to chromatin 
fragmentation.23 Thus, ChIP is also known as the gold standard to investigate DNA-protein 
interactions from a broad aspect to localize those proteins involved in epigenetic regulation (e.g., 
those recruited by histone modifications).24   
ChIP-seq is indeed a powerful tool in elucidating epigenetic regulating network. With 
ChIP-seq and its derivative methods, identification and validation of modifiers and regulators 
related to aging, cellular development, disease/cancer progression, and other crucial biological 
processes have been realized, along with the disclosure of underlying epigenetic regulating 
mechanisms.25-30 However, it has several limitations that people want to improve upon. One major 
challenge is the large input sample size requirement. Traditionally, ChIP-seq requires more than 
106 cells as starting materials for one mark to ensure effective enrichment of DNA related to 
protein of interest, which is unfeasible for clinical biopsies containing fewer than 103 cells each or 
samples of rare cell populations.22, 31 A second challenge is the lack of sensitivity to sample 
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heterogeneity due to the aggregation of DNA from all cells present in the sample of interest. Cells 
are usually lysed, digested, and analyzed in bulk, which buries possible signals from small numbers 
of abnormal or novel features. Third, robustness and reproducibility of ChIP-seq need to be 
enhanced. ChIP-seq usually relies largely on an operator’s skill to complete a large number of 
manual processing steps, thus the results can vary to a large extent simply depending on 
qualification of the operator. Fourth, ChIP-seq experiments are inherently low throughput, where 
they target only one protein modification per sample volume. When combined, these factors 
complicate the use of conventional ChIP-seq in routine clinical practices, such as those studying 
large patient cohorts including monitoring both healthy and abnormal samples across human life 
span.32 Efforts have been made to improve ChIP-seq and typical examples are those using 
continuous microfluidics as the latter has been widely known to offer the advantages of automation 
and reduced sample sizes and reagent consumption. The Quake group has been one of the pioneers 
in enabling microfluidic low-input cells and single-cell epigenomic sequencing and profiling. They 
have developed automated microfluidic device-based ChIP protocol (AutoChIP) that allows 2000-
cell equivalent DNA to be enriched with similar quality of ChIP DNA compared to conventional 
methods.33, 34 Multi-layered and valve-assisted ring structures were designed to control sample 
loading, bead washing, and DNA eluting. By integrating multiple AutoChIP structures, they have 
also improved the throughput of ChIP experiments with 10,000-cell equivalent chromatin as 
starting material per ring.35 The Lu lab has also been investigating epigenomic assays for fewer 
cells by exploiting microfluidic chamber structures. By using valves to control cell lysate loading 
and capture DNA elution, they have shown that fragmented chromatin from 100 cells can be 
treated microfluidically with high enough quality for subsequent DNA analysis.36 Further 
integration of sonication and immunoprecipitation enabled on-chip shearing of chromatin in 
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addition to DNA capture.37 Their most recent publication also showed that by fabricating multiple 
microfluidic beds ChIP targeting two marks could be carried parallelly.38 These improvement were 
all enabling more capable ChIP on smaller sample sizes; however, they all rely on continuous 
microfluidics which the device size becomes the limiting factor of the sample size that is 
compatible with the device: only a fixed amount of fragmented chromatin that fits the size of the 
microfluidic chamber, and fits with the amount of beads functionalized with antibodies that are 
(pre-)loaded into the chamber can be processed, too big sample size leading to sample volume 
pushed out of the chamber thus sample loss, too small size leading to a mismatch with the number 
of antibody-functionalized beads thus deviating from the optimized ChIP efficiency. Additionally, 
not all microfluidic ChIP starts with cells directly, some using pre-fragmented chromatin as 
starting materials. Hence, space for enhancement still exists for ChIP automation and minimization, 
and droplet microfluidics is a potential tool for such optimized ChIP.  
Droplet microfluidics is becoming a valuable tool for various applications such as single-
cell analysis, complex biological and chemical assays, diagnostics, DNA sequencing, and drug 
screening.39-42 The basic principle to generate droplets includes segmenting aqueous streams with 
a continuous, immiscible, and inert oil flow, and each droplet functions as an independent 
microreactor surrounded by oil and not touching the inner side of the channel, indicating little 
nonspecific adsorption of samples to the device or contamination with each other.43, 44 The volume 
of the droplets is tunable by changing flow rate values and ratios between continuous and dispersed 
phases, and typically ranges from femtoliters to nanoliters thus suitable for single cell analysis.45-
58 Reliable and precise manipulation of individual droplet has emerged recently covering droplet 
coalescence, splitting, injection, and content mixing.59-69 Additionally, previous studies have 
shown that mixing occurs very rapidly within the droplets due to convective flow profile inside 
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them, allowing for more efficient chemical and biological reactions and thus shorter operation time 
for experiments.43, 70-72 This is highly advantageous over conventional continuous-flow 
microfluidics, which offers low Reynolds numbers and laminar flows, resulting in rather slower 
mixing predominated by molecular diffusion, as it means droplet microfluidic devices need little 
to no external mechanisms to help mixing, leading to the simplification of device design and 
operation.43 Furthermore, as droplets can be continuously generated and cell distribution in 
droplets follow Poisson distribution, a flexible sample size can be processed on a droplet 
microfluidic device without an affected processing performance by keeping it operating until all 
the volume is segmented into droplets as long as the cell suspension density does not surpass the 
theoretical upper limit, that is one cell per generated droplet. This flexible sample size feature is 
practically useful for clinical sample ChIP, as knowing the specific cell numbers per sample may 
be impossible in real life.  
With all the advantages discussed, a droplet microfluidic strategy to automate and improve 
ChIP was described in detail in this chapter. Using a slightly modified cellular chromatin MNase 
processing device adapted from Chapter 3, cells were lysed and digested simultaneously inside 
droplets and antibody-functionalized beads suspended in quenching buffer were injected into these 
droplets at the end of the device, allowing ChIP to happen. The collected droplets were loaded to 
a second device to wash the chromatin-antibody-bead conjugates to reduce non-specific binding 
before eluting and extracting the bound DNA. The majority of the chapter discussed the validation 
of ChIP under the droplet microfluidic conditions, with preliminary data of droplet microfluidic 
ChIP briefly commented. Quantitative PCR on gene loci associated with the targeted histone 
modification marks was executed to evaluate the ChIP enriching efficiency of the chromatin 
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regions containing tested marks. Directions for further optimization to improve ChIP in flowing 
droplet microfluidic format were listed and explained in the end.  
 
Materials and Methods 
Buffer recipes  
Lysis buffer (pH 7.9) contained 10 mM HEPES, 1.5 mM magnesium chloride (MgCl2), 10 
mM potassium chloride (KCl), and 0.5% (w/v) IGEPAL-CA630 (Sigma-Aldrich, St. Louis, MO). 
Digestion buffer (pH 7.5) contained 20 mM Trizma hydrochloride (Tris-HCl), 15 mM sodium 
chloride (NaCl), 60 mM KCl, 5 mM calcium chloride (CaCl2), 0.15 mM spermine, and 0.5 mM 
spermidine. 2× STOP/ChIP buffer or quenching buffer (pH 8) contained 100 mM Tris-HCl, 20 
mM ethylenediaminetetraacetic acid (EDTA), 200 mM NaCl, 2% Triton X-100, and 0.2% sodium 
dodecyl sulfate (SDS). Low salt immune complex wash buffer (pH 8.1) contained 20 mM Tris-
HCl, 2 mM EDTA, 150 mM NaCl, 0.1% SDS, and 1% Triton X-100. High salt immune complex 
wash buffer (pH 8.1) contained 20 mM Tris-HCl, 2 mM EDTA, 500 mM NaCl, 0.1% SDS, and 
1% Triton X-100. LiCl immune complex wash buffer (pH 8.1) contained 10 mM Tris-HCl. 1 mM 
EDTA, 250 mM LiCl, 1% IGEPLA-CA630, 1% sodium deoxycholate. TE buffer (pH 8.1) 
contained 10 mM Tris-HCl and 1 mM EDTA. 2×elution buffer (pH 8.0, recipe from Mayo Clinic, 
Rochester) contained 20 mM Tris-HCl, 20 mM EDTA, 300 mM NaCl, and 2% SDS. 
 
Cell culture and cell suspension preparation 
HeLa cells were cultured at 37°C with 5% CO2 in the DMEM medium (Gibco DMEM high 
glucose, Catalog No. 11965092, Fisher Scientific) supplemented with 10% v/v fetal bovine serum. 
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After aspirating existing media and washing with cold PBS, the cells were treated with 3-mL, 0.5% 
trypsin-EDTA for 5 minutes at 37°C and added 7-mL complete growth media to quench trypsin’s 
activity. Then the cell suspension was transferred to a 50-mL conical tube and pelleted at 800×g 
for 5 min at 4°C, washed with cold PBS buffer, and resuspended into the density-adjusted PBS 
buffer to a defined concentration as described below. After resuspension, cells were stored on ice 
for use. All digestion and ChIP experiments of HeLa cells (both on chip and in tube) were carried 
out with 30 µL of cell suspension at a density of 4 million cells per mL, unless otherwise stated.  
 
Immunoprecipitation bead functionalization 
For each ChIP reaction, 30-µL protein G Dynabead slurry for immunoprecipitation 
(Invitrogen, Catalog No. 10003D and 10004D, Thermo Fisher Scientific) was washed by 100-µL 
1× STOP/ChIP Buffer for a total of three times. Washed Dynabeads was resuspend in 100-µL 1× 
STOP/ChIP Buffer. A specific volume of antibody stock solution was added to the beads for an 
expected amount. For example, 10-µL, 0.2 mg/mL anti-H3K4me3 antibody (Anti-Histone H3 
(trimethyl K4) antibody-ChIP Grade, Catalog No. ab8580, Abcam) was added to the 100-µL bead 
suspension for a ChIP reaction with 2-µg antibody. Beads were incubated with antibodies at 4 °C 
on a rotator for at least 2 hours. After removal of supernatant, the functionalized beads were 
washed by 100-µL 1× STOP/ChIP Buffer for a total of three times and supernatant aspirated. The 
beads were ready for ChIP.  
 
Microfluidic device fabrication 
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Microfluidic devices were generated using standard photolithography and soft lithography 
methods with details described in Chapter 2 and the brief summary in Chapter 3 and 4. The pattern 
of the device was designed in AutoCAD (schematic for the device’s design was shown in Figure 
5-1). Briefly, SU8 2025 (MicroChem Corp, Westborough, MA) was first spin coated (PWM 32, 
Headway Research, Inc) onto the silicon wafer at 2000 rpm for 30 seconds to give a 40-µm thick 
layer. After soft baking, the resist layer was exposed to a UV lamp (Optical Associates, 
Incorporated) through the first-layer photomask. After post-exposure baking, the patterned wafer 
was developed in propylene glycol monomethyl ether acetate (PGMEA) (Sigma-Aldrich, St. Louis, 
MO) and dried under nitrogen. SU8 2050 was then spin coated onto the patterned wafer at 1150 
rpm for 30 seconds to give a 160-µm thick layer. After soft baking, the resist was exposed to UV 
through the second-layer photomask and then developed as described above. After that, the PDMS 
base and elastomer curing agent (Momentive RTV 615 kit, R.S. Hughes, Carol Stream, IL) were 
mixed at a mass ratio of 10:1 and degassed under vacuum before poured over the master. After 
curing and peeled off from the master, the PDMS replica was punched for tubing inserting holes 
with blunt-tip biopsy needles (18 gauge for inlets, 20 gauge for the outlet and electrolyte inlets). 
The device replicas were then sonicated in water for 5 min and dried with nitrogen to remove any 
PDMS debris. In parallel, a base layer was created on a glass slide by spinning a degassed, 10:1 
PDMS base:elastomer mixture onto the glass microscope slide. This base layer was partially cured 
for 8 min before the microfluidic replica was placed on top with gentle pressure, followed by a 
final 30 min bake to fully bond the microfluidic device. Alternatively, the PDMS replica and the 
microscope glass slide could also be put into a plasma chamber (Plasma cleaner PDC-32G, Harrick 
Plasma, Inc), treated for 30 s at high level of oxygen plasma with 1 torr of air pressure, and 
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assembled together by attaching the treated side of the PDMS replica to the treated side of the 
glass slide. A 30-min bake to fully bond the microfluidic device is still necessary.   
 
Microfluidic device operation 
Solutions were delivered to the device through 24-gauge PTFE tubing (Cole-Parmer, 
Vernon Hills, IL) controlled by syringe pumps (Pump 11 Pico Plus Elite, Harvard Apparatus). The 
immiscible oil phase was the fluorinated oil Novec 7500 (3M, St. Paul, MN) with 2% (w/w) 
perfluoropolyether polyethylene glycol block co-polymer surfactant (RAN Biotechnologies, Inc. 
Beverly, MA). The tubing to deliver cells to the device was treated with 1% (w/v) Pluronic F127 
(Sigma-Aldrich, St. Louis, MO)-containing PBS solution overnight and prefilled with PBS buffer. 
Figure 5-1 Schematic of the photomask design of the droplet microfluidic device for on-chip ChIP. 
The red parts were the first layer of 40-µm thickness, and the black part the second layer of 160-
µm thickness. The two layers were printed on two individual masks. They should be aligned to 
ensure the connection of the channels (shown as the overlap between the red and black). The zoom-




Two sets of electrolyte channels for the two injection sites on the microfluidic device for MBA 
and MNase samples respectively were all filled with a 3M sodium chloride solution. For each set, 
two clamps from electrodes of an in-house built DC-AC converter (12V DC input, 0-360V AC at 
36 kHz as output), which was connected to a power supply (DC regulated power supply, TENMA 
T2-6628), were connected to the syringe needles supplying the electrolyte channels to form a 
complete circuit for the AC electric field.  
Prior to experiments, microfluidic devices were treated with Aquapel (Pittsburgh Glass 
Works, Pittsburgh, PA) as described previously53 to give a hydrophobic coating throughout sample 
processing. Optiprep (Sigma-Aldrich, St. Louis, MO) was added to PBS buffer to obtain a final 
density of 1.07 g/mL at a 21.9% (v/v) concentration. Cells were resuspended in this density-
adjusted PBS buffer to reduce clumping and settling in the tubing. Cell suspensions were drawn 
into the pre-treated tubing separated from the pre-filled buffer by a plug of air. The combined lysis-
digestion buffer was prepared by mixing 30-µL MNase (2000 GU/µL; New England Biolabs, 
Ipswich, MA), 120-µL digestion buffer, and 300-µL lysis buffer. Antibody-functionalized beads 
were suspended in the 2×STOP/ChIP buffer at a ratio of 100 µL of buffer per number of beads 
from 50 µL of original bead slurry mixed with 1 µL of protease inhibitor (Protease inhibitor 
cocktail set II, Catalog No. 539132, EMD Millipore Corporation). This ratio is the same as that 
described in bead functionalization section but scaled up the total volume. The syringe for bead 
containing STOP/ChIP buffer was pre-filled with normal 2×STOP/ChIP buffer so that the 100 µL 
bead containing quenching buffer was only in the PTFE tubing.  
Flow rates of oil (6 µL/min), cell suspension (2 µL/min), lysis-digestion reagent (2 µL/min), 
2×STOP/ChIP buffer with antibody-functionalized beads (4 µL/min), and spacing oil (10-14 
µL/min) were optimized to ensure that droplets with appropriate size were generated, droplets 
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travelled across the delay channels for appropriate time to allow thorough MNase digestion, and 
quenching buffer containing antibody-functionalized beads was injected into every droplet at the 
injection sites. Droplets were collected via 30-gauge PTFE tubing (Cole-Parmer) into 0.6-mL 
tubes for the subsequent bead wash. Device operation was visualized using a high-speed camera 
(Phantom Miro Ex2) mounted onto a stereoscope (Leica M80). 
 
Chromatin immunoprecipitation (ChIP) under multiple conditions 
Traditional ChIP was carried out as described below. Per ChIP reaction, 30-µL combined 
lysis-digestion buffer with MNase was incubated with 30-µL cell suspension for 3.5 minutes and 
quenched with 60-µL 2×STOP/ChIP buffer. After 5 minutes of incubation, 880-µL 1×STOP/ChIP 
buffer was added to the fragmented chromatin and mixed thoroughly. 900-µL fragmented 
chromatin was combined with prepared antibody-functionalized beads with 4.5-µL protease 
inhibitor and incubated for immunoprecipitation at 4 °C on a rotator overnight. 9-µL fragmented 
chromatin from the same source was saved as 1% input, mixed with 91-µL 1×elution buffer, and 
frozen at -20°C until ready for DNA extraction. After overnight incubation, ChIP reaction mix was 
set on a magnetic rack for targeted chromatin-antibody-bead conjugates washing. After removal 
of chromatin solution, 1-mL low salt immune complex wash buffer was aliquoted to each ChIP 
reaction and mixed thoroughly. The reaction was kept on the rotator at 4°C for 5 minutes. Then 
the wash buffer was removed. Repeat with three other wash buffers to remove non-specific bound 
chromatin. The washed chromatin-antibody-bead conjugates were resuspended in 100-µL 
1×elution buffer. The ChIP sample was ready for DNA extraction and purification.  
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ChIP in tube mimicking on-chip conditions (also referred to as off-chip) was carried out as 
described below. Per ChIP reaction, the prepared antibody functionalized beads were suspended 
in 60-µL 2×STOP/ChIP buffer mixed with 0.6-µL protease inhibitor. 30-µL combined lysis-
digestion buffer with MNase was incubated with 30-µL cell suspension for 3.5 minutes and 
quenched with 60-µL bead containing 2×STOP/ChIP buffer to quench the digestion and start 
immunoprecipitation in one pot. The reaction was then incubated overnight at 4 °C on a rotator. 
After overnight incubation, the ChIP reaction mix was washed with the four types of wash buffer 
and resuspended in 1×elution buffer as described above. One simultaneously lysed and digested 
chromatin quenched with normal 2×STOP/ChIP buffer (i.e., no beads suspended inside or protease 
inhibitor) was prepared as 100% input for this format of ChIP.  
ChIP on chip was carried out as described in the section of “Microfluidic device operation”. 
Collected droplets were either incubated overnight at 4 °C and manually washed with the four 
wash buffer solutions (in this case, the collecting tube should be 1.5-mL instead of 0.6-mL as 
described in the referred section) or washed by a droplet microfluidic device right after collection. 
After incubation overnight but before manual washing or after device washing, droplets were 
coalesced by adding 50-µL 1H,1H,2H,2H-perfluoro-1-octanol (Sigma-Aldrich, St. Louis, MO). 
Aqueous phase with beads and oil phase were separated by centrifugation at 8000 rpm for 1 min 
at room temperature in a tabletop microcentrifuge (Centrifuge 5418, Eppendorf, Hauppauge, NY). 
Aqueous supernatant was removed leaving only beads capturing targeted chromatin. If beads were 
device washed, they would be resuspended in 100-µL 1×elution buffer directly. Otherwise 
resuspending in 100-µL 1×elution buffer after manual washing. Finally, these beads The ChIP 




ChIP DNA and input DNA extraction and purification 
For each 100-µL elution buffer suspended beads or input fragmented chromatin, 2-µL 
RNase A (10 mg/mL, Sigma-Aldrich, St. Louis, MO) was added to degrade RNA by incubating 
at 65 °C for 1 hour. 3-µL Proteinase K (10 mg/mL, ThermoFisher Scientific, Grand Island, NY) 
was added consecutively to degrade proteins by incubating at 65 °C for 2 hours. During these three 
hours, bound chromatin was also eluting from the beads into the aqueous phase. Aqueous phases 
were collected to clean DNA LoBind tubes. ChIP DNA and 1% input were extracted and purified 
by QIAgen MinElute kit, eluted to 15-µL EB buffer, and 100% input DNA was extracted and 
purified by QIAquick PCR purification kit, eluted to 50-µL EB buffer.  
 
Characterization of input DNA 
The concentration of purified DNA was determined using the Qubit dsDNA assay 
(ThermoFisher Scientific, Grand Island, NY). The size distribution of the input DNA was 
characterized using a Bioanalyzer (Agilent). All samples were diluted to or below 500 pg/µL 
consistent with Bioanalyzer sample submission requirements. The percentage of 
mononucleosomal DNA in the total DNA was obtained from the Bioanalyzer software.  
 
Quality control of ChIP DNA 
Three loci (Brg1_TSS, Myt1_TSS, SAT-alpha) associated with different histone 
modification marks (H3K4me3, H3K27me3, and H3K9me3, respectively) were selected as targets 
to assess the enrichment efficiency of ChIP. An intergenic locus (C19 intergenic region73) was 
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used as reference evaluating the digested chromatin’s background for ChIP. Sequences of primer 
pairs for these four regions were listed in Table B-2 in APPENDIX B.  
Quantitative PCR reaction per well on the 384-well reaction plate (Applied Biosystems 
Catalog No. 4309848, Fisher Scientific) was set up according to the manufacturer’s recommended 
parameters. Briefly, for each target, 10-µL PowerUp™ SYBR™ Green master mix (Applied 
Biosystems Catalog No. A25776, Fisher Scientific) was mixed with 2-µL forward primer (5 µM) 
and 2-µL reverse primer (5 µM). Then 2 to 3 µL of DNA template was added to the mix depending 
on the DNA concentration to ensure appropriate amount of DNA was used. The volume was made 
up to 20 µL by adding appropriate volume of nuclease-free water. After setting up the PCR plate, 
the experiment was run on 7900HT Fast Real-Time PCR system (Applied Biosystems) with the 
standard parameter setup at the DNA sequencing core facility (University of Michigan). Fold 
change of targeted loci (posi) between ChIP DNA (IP) and input DNA (Inp) was calculated using 
equation (5.1) to assess the efficiency of ChIP enrichment of chromatin regions containing each 
histone modification mark. 
𝑙𝑜𝑔2 𝑓𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 = 𝑐𝑡(𝐼𝑃,𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒) −  𝑐𝑡(𝐼𝑃,𝑝𝑜𝑠𝑖) − (𝑐𝑡(𝐼𝑛𝑝,𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒) −  𝑐𝑡(𝐼𝑛𝑝,𝑝𝑜𝑠𝑖))  (5.1) 
 
Results and Discussion 
 The development of ChIP protocol usually contains the optimization of the amount ratio 
among antibody, beads, and fragmented chromatin, and the confirmation of chromatin’s 
fragmentation efficiency.24, 36, 74 The same parameters were evaluated here as well. As shown in 
Figure 5-2, when keeping the bead amount and fragmented chromatin amount consistent, 
increasing the amount of antibody would increase the amount of captured ChIP DNA (until all 
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possible chromatin fragments containing the corresponding mark was pulled down and capture 
efficiency reaching saturation). Importantly, the fact that significantly smaller amount of DNA 
was captured when no antibody was functionalized onto the beads (p < 0.01 comparing 0-µg 
antibody groups and 1-µg antibody groups) confirmed the quality of selected beads and protocol 
(i.e., ChIP in tube mimicking on-chip conditions) as little non-specific binding happened verifying 
little noise of the reaction. Additionally, the input sample contained 1-µg fragmented DNA, thus 
the pull-down efficiency of the four tested antibody amounts were 0.22%, 0.56%, 0.66%, and 
0.98%, respectively, agreeing with the collaborators’ empirical observation at Mayo Clinic, 
Rochester.  
 
Figure 5-2 ChIP DNA pulled down by various amount of anti-H3K4me3 antibody per reaction. 
Error bars were standard deviations from three technical replicates under each condition, and each 
replicate had chromatin digested from individual 30-µL cell suspension aliquot. 
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After checking the captured ChIP DNA’s amount, input samples’ digestion patterns should 
also be checked to ensure expected fragmentation happened. Figure B-6 confirmed that most 
chromatin became mononucleosomes after the simultaneous lysis and digestion, with mono ratio 
at 80.6%. Since the input sample was prepared the same way as those used for ChIP, this result 
indicated that the fragmented chromatin used for ChIP were mostly mononucleosomes, thus if 
sequenced, the localization of H3K4me3 mark could be more precisely determined after mapping 
the reads containing short templates to the reference genome compared to those carried out with 
bigger fragments.  
Besides the captured ChIP DNA and fragmentation of chromatin, qPCR quality control 
experiments were even more important, and it would confirm the enrichment and the enriching 
specificity reached by the specific ChIP reaction. Specifically, among the three tested loci (not 
including the reference locus), only the one within the gene region of Brg1 (Brg1_TSS) should be 
enriched in the ChIP reactions targeting H3K4me3. This is because the encoded product protein 
Brg1 is a transcription activator, a component of many chromatin remodeling complexes including 
SWI/SNF, thus should always be activated in HeLa cells and associated with the well-known 
active mark H3K4me3. On the other hand, Myt1_TSS and SAT-alpha should not have this mark as 
the former encodes a fat component dominantly expressed in the nervous system but not cervical 
originated cells and the latter represents repetitive satellite regions associated with H3K9me3 in 
centromeres. Figure 5-3 proved that all three tested antibody amounts enriched significant amount 
of DNA that once formed into nucleosomes with histone H3 marked by trimethylation on lysine 
4. The fold change of Brg1_TSS normalized to C19_intergenic post compared to prior to ChIP 
surpassed empirical threshold 5, or ∆∆Ct surpassed 2.32 (i.e., log2(fold change) in eq 5.1) and were 
significantly higher than that of the bead control (i.e., 0-µg antibody ChIP) indicating the 
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concentration of the appropriate chromatin regions containing H3K4me3 by ChIP, while the fold 
change of Myt1_TSS were much lower in all conditions especially in the case of 2-µg antibody per 
ChIP (the fold change was approximately 1), indicating no significant enrichment of non-specific 
chromatin regions. Although the fold change of SAT-alpha was around the threshold, it was 
consistent across all conditions including the bead control and thus indicated that perhaps since 
SAT-alpha was repetitive, the multiple copies of that gene contributed to the non-specific pull 
down into the ChIP DNA and therefore it was not specifically concentrated by the antibody. 
Together, results in Figure 5-3 validated that the ChIP conditions mimicking on-chip ChIP allowed 
successful selective enrichment, which strengthened the confidence of the success in droplet 
microfluidic ChIP development. 2-µg anti-H3K4me3 antibody was selected as the optimal amount 
for this mark because of its significant enrichment of associated gene locus but lowest non-specific 





 Additionally, in the case of the project to be developed in this chapter, one additional aspect 
needed confirmation: Whether a separately prepared fragmented chromatin can be used as input 
sample (100% input), instead of taking parts from the fragmented chromatin added to antibody-
bead conjugates. After all, most traditional ChIP protocols take input samples for future analysis 
from chromatin prepared in bulk before aliquoting for ChIP.75 Therefore, ChIP reactions were 
carried out in three formats to evaluate the concern discussed above. The antibody used here 
targeted H3K27me3, which was known to be a repressive mark, thus only the locus MYT1_TSS 
Figure 5-3 Average fold change results of ChIP using various amount of anti-H3K4me3 
antibody per reaction. Error bars were standard deviations from three technical replicates under 
each condition. BRG1 stood for fold change of Brg1_TSS normalized to C19_intergenic in ChIP 
DNA compared to the input sample, MYT1 stood for fold change of Myt1_TSS normalized to 
C19_intergenic, hSAT stood for fold change of SAT-alpha normalized to C19_intergenic.  
127 
 
should be associated with this mark as the related gene encodes a protein not expressed in the cell 
line. Format 1 resuspended antibody-functionalized beads in the combined lysis and digestion 
buffer and followed the protocol “ChIP in tube mimicking on-chip conditions” described in the 
section of “Chromatin immunoprecipitation (ChIP) under multiple conditions” in “Materials and 
Methods” for the rest of the experiment. Format 2 followed the protocol “ChIP in tube mimicking 
on-chip conditions” exactly. Format 3 followed the protocol “traditional ChIP” exactly 
contributing two 1% input samples. Duplicates were tested for each condition and the results were 
shown in Figure 5-4. The y axis was the fold change calculated based on 1% input taken from 
format 3 replicate 1 (F3_1_1%inp). Notice that the fold changes of three gene loci of the 100% 
input sample and the other 1% input sample were all close to 1, demonstrating that the chromatin 
fragmentation was consistent across replicates and parts of replicates, showing that simultaneously 
lysed and digested native chromatin suspension was homogenized well and that taking 1% out of 
100% or taking 100% directly would not disturb the normalizing base line for qPCR. This result, 
along with the digestion patterns of all three input samples shown in Figure B-8 to 10, really 
strengthened the fidelity of the qPCR data in Figure 5-3. Furthermore, the 2nd replicate of format 
2 and the 1st replicate of format 3 had no convincing Ct values thus no fold change values available 
due to little copies of Brg1_TSS in the samples, indicating that the antibodies targeted H3K27me3 
with high specificity, showing little enrichment of gene loci not associated with the targeted 
histone modification. Both format 2 and 3 but not format 1 showed effective enrichment of 
Myt1_TSS with fold change similar to or over 5, validating that the corresponding two ChIP 
protocols were effective. One thing to notice is that both replicates in format 3 had fold change of 
SAT-alpha close to 1, which was expected as this gene loci was not supposed to be associated with 
either H3K4me3 or H3K27me3, but only H3K9me3. Such low enrichment of this gene locus was 
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not obtained in ChIP carried out in the conditions mimicking on-chip version using either antibody. 
This perhaps indicated that a bigger chromatin volume contributed to even less non-specific 
binding of any chromatin fragments to the antibody-bead conjugates as sufficient 
mixing/disturbing and enough dissipating volume existed when using the same volume and 
number of beads. This corresponded with previous literature76 and the protocol of macroscale ChIP 
carried out by my collaborator at Mayo Clinic. However, as enlarging the fragmented chromatin’s 
volume on chip would not be applicable for now, the results here confirming that the small-volume 
fragmented chromatin still qualifies for ChIP were exciting for the continuous development of the 
project.  




Further comparison between 100% input samples prepared on chip (using the same device 
shown in Figure 5-1 with 2×STOP/ChIP buffer without beads) and in tube validated the 
consistency of chromatin fragmentation to a wider extent. As shown in Figure 5-5, the fold change 
of three gene loci in both in tube 100% input samples were all close to 1 using on-chip 100% input 
as the reference sample, though the on-chip ChIP did not work efficiently. This proved that for the 
ease of future development, input samples could be generated simply in tube without the need to 
operate another device if materials are limited and the qPCR results would still be convincing; 
Figure 5-4 Fold change results of ChIP under three formats using 2-µg anti-H3K27me3 antibody 
per reaction. BRG1 stood for fold change of Brg1_TSS normalized to C19_intergenic in ChIP 
DNA compared to the input sample F3_1_1%inp, MYT1 stood for fold change of Myt1_TSS 




however, if sample consistency was emphasized, on-chip prepared 100% input would yield 
similarly qualified results as well. 
 
After the in-tube validation mimicking on-chip conditions obtaining qualified ChIP results 
using small volumes of fragmented chromatin and 100% input samples (prepared in tube), the 
characterization of optimal ratio among antibody, beads, and chromatin amount, and the 
characterization of immunoprecipitation incubation time duration (results shown in Figure B-7), 
ChIP on chip with manual washing was tested using 2-µg anti-H3K27me3 antibody per reaction 
Figure 5-5 Fold change results of ChIP using 2-µg anti-H3K27me3 antibody per reaction. BRG1 
stood for fold change of Brg1_TSS normalized to C19_intergenic in ChIP DNA compared to the 
input sample F3_1_1%inp, MYT1 stood for fold change of Myt1_TSS normalized to 
C19_intergenic, hSAT stood for fold change of SAT-alpha normalized to C19_intergenic. Each 
condition (on chip and in tube) had duplicates.  
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following “ChIP on chip” described in the section of “Chromatin immunoprecipitation (ChIP) 
under multiple conditions” in “Materials and Methods”. As shown in Figure 5-6, on-chip ChIP 
(orange) did not enrich the associated gene locus Myt1_TSS as effectively as in-tube ChIP 
mimicking on-chip conditions (green), while the non-associated SAT-alpha fold change spread out 
wider and averagely higher. However, the fact that Brg1_TSS was not enriched by on-chip ChIP 
was promising, indicating the (partial) existence of ChIP specificity on chip.  
 
Figure 5-6 Fold change results of ChIP on chip (on-IP) and ChIP in tube mimicking on-chip 
conditions (off-IP). BRG1 stood for fold change of Brg1_TSS normalized to C19_intergenic in 
ChIP DNA compared to the input samples, MYT1 stood for fold change of Myt1_TSS normalized 
to C19_intergenic, SAT stood for fold change of SAT-alpha normalized to C19_intergenic. Input 
samples were in tube 100% input. On-chip ChIP had 6 replicates, ChIP in tube mimicking on-chip 
conditions had 10 replicates. 
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During the experiments, problems of on-chip ChIP were noticed and need to be solved to 
improve the enrichment efficiency. First, the beads resuspended in 2×STOP/ChIP buffer did not 
remain suspended or homogenized during the entire ChIP process (Figure 5-7a, no beads coming 
out at that specific moment). Beads precipitated easily during processing and aggregated with each 
other (Figure 5-7b and c). This led to the fact that the droplets injected with beads were not 
injected with same numbers of beads, and many droplets would not be injected with any antibody-
bead conjugates. This means that part of the chromatin was not immunoprecipitated at all and thus 
sample bias happened during on-chip ChIP, as well as potential deviation from the optimal ratio 
among antibody, beads, and chromatin amount. Second, not all droplets contain cells, but the 
injection had to remain all the time. This caused waste of antibody-bead conjugates where antibody 
can be expensive and precious. Third, after collecting of beads containing droplets, whether for 
manual wash or after device wash for captured DNA elution directly, some magnetic beads were 
trapped in the oil phase and hard to be recovered. Bead loss contributed to the uncertainty of 
enrichment evaluation: does the better or worse fold change come from the fact that less ChIP 
DNA were eluted due to fewer beads, so it is artefact? 
 
Therefore, a strategy to quantitatively load antibody functionalized beads that remain 
suspended needs to be developed in order to reach a quantitative ChIP condition. Controlling bead 
Figure 5-7 Illustration of bead containing 2×STOP/ChIP buffer injection problems. (a) No bead 
coming out. (b) Many beads coming out but on one edge. (c) Aggregated beads coming out as 
individual groups. Scale bars represent 200 µm. 
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loss is also a significant aspect to improve on-chip ChIP. Furthermore, if a sorting mechanism can 
be integrated to the workflow teasing out the empty droplets without cells after the improvement 
mentioned above, expensive reagents such as antibody can be saved more. It is also more feasible 
controlling antibody-bead amount per cell or per two cells if the droplets are sorted and the 
percentage of single-cell and double-cell containing droplets are known. When these aspects are 
all improved, on-chip ChIP can be quantitatively evaluated which is more accurate than what has 




 In this chapter, the characterization, optimization, and validation of droplet microfluidic 
ChIP was described in detail. With the existing data, two important aspects of the new ChIP format 
were validated demonstrating the possibility of doing ChIP in droplet microfluidic format. First, 
simultaneous lysis and digestion happening on the MNase processing device generated qualified 
fragmented chromatin for ChIP reaction with majority being mononucleosomes. Second, the ChIP 
conditions happening on the MNase processing device (adding antibody-bead conjugates to the 
chromatin containing droplets with quenching buffer directly without aliquoting 1% input as 
traditional ChIP does but using separately prepared 100% input) allowed convincing qPCR results 
and thus successful ChIP to enrich appropriate regions of chromatin. Though preliminary on-chip 
ChIP did not concentrate targeted regions significantly, the problems existing in the current device 
systems were pointed out and the potential solutions planned. Future work needs to be done as 





1. H. Kimura, Journal of human genetics, 2013, 58, 439-445. 
2. D. Corujo and M. Buschbeck, Cancers, 2018, 10. 
3. A. J. Bannister and T. Kouzarides, Cell Res, 2011, 21, 381-395. 
4. Y. Obata, Y. Furusawa and K. Hase, Immunology and cell biology, 2015, 93, 226-232. 
5. Z. Chen, S. Li, S. Subramaniam, J. Y. Shyy and S. Chien, Annu Rev Biomed Eng, 2017, 
19, 195-219. 
6. E. S. Chrun, F. Modolo and F. I. Daniel, Pathology, research and practice, 2017, 213, 
1329-1339. 
7. M. Vermeulen, H. C. Eberl, F. Matarese, H. Marks, S. Denissov, F. Butter, K. K. Lee, J. 
V. Olsen, A. A. Hyman, H. G. Stunnenberg and M. Mann, Cell, 2010, 142, 967-980. 
8. J. Li, X. Xing, X. Zhang, B. Liang, Z. He, C. Gao, S. Wang, F. Wang, H. Zhang, S. Zeng, 
J. Fan, L. Chen, Z. Zhang, B. Zhang, C. Liu, Q. Wang, W. Lin, G. Dong, H. Tang, W. 
Chen, Y. Xiao and D. Li, Environ Pollut, 2018, 234, 127-135. 
9. F. S. Howe, H. Fischl, S. C. Murray and J. Mellor, BioEssays : news and reviews in 
molecular, cellular and developmental biology, 2017, 39, 1-12. 
10. C. Wang, J. E. Lee, B. Lai, T. S. Macfarlan, S. Xu, L. Zhuang, C. Liu, W. Peng and K. Ge, 
Proceedings of the National Academy of Sciences of the United States of America, 2016, 
113, 11871-11876. 
11. W. A. Whyte, S. Bilodeau, D. A. Orlando, H. A. Hoke, G. M. Frampton, C. T. Foster, S. 
M. Cowley and R. A. Young, Nature, 2012, 482, 221-225. 
12. G. Ding, W. Li, J. Liu, Y. Zeng, C. Mao, Y. Kang and J. Shang, Biomedicine & 
pharmacotherapy = Biomedecine & pharmacotherapie, 2017, 94, 326-331. 
13. A. Rada-Iglesias, R. Bajpai, T. Swigut, S. A. Brugmann, R. A. Flynn and J. Wysocka, 
Nature, 2011, 470, 279-283. 
14. X. Yang, B. Hu, Y. Hou, Y. Qiao, R. Wang, Y. Chen, Y. Qian, S. Feng, J. Chen, C. Liu, 
G. Peng, F. Tang and N. Jing, Cell Res, 2018, 28, 593-596. 
15. Y. Qu, Q. Yang, J. Liu, B. Shi, M. Ji, G. Li and P. Hou, Theranostics, 2017, 7, 2092-2107. 
16. S. Li, S. Ali, X. Duan, S. Liu, J. Du, C. Liu, H. Dai, M. Zhou, L. Zhou, L. Yang, P. Chu, 
L. Li, R. Bhatia, D. E. Schones, X. Wu, H. Xu, Y. Hua, Z. Guo, Y. Yang, L. Zheng and B. 
Shen, Cell reports, 2018, 23, 389-403. 
17. R. Z. Jurkowska, S. Qin, G. Kungulovski, W. Tempel, Y. Liu, P. Bashtrykov, J. 
Stiefelmaier, T. P. Jurkowski, S. Kudithipudi, S. Weirich, R. Tamas, H. Wu, L. 
Dombrovski, P. Loppnau, R. Reinhardt, J. Min and A. Jeltsch, Nature communications, 
2017, 8, 2057. 
18. H. Takeshima, M. Wakabayashi, N. Hattori, S. Yamashita and T. Ushijima, Cancer 
Research, 2014, 74, 2314-2314. 
19. Y. Atlasi and H. G. Stunnenberg, Nature reviews. Genetics, 2017, 18, 643-658. 
20. D. S. Johnson, A. Mortazavi, R. M. Myers and B. Wold, Science, 2007, 316, 1497-1502. 
21. R. Jothi, S. Cuddapah, A. Barski, K. Cui and K. Zhao, Nucleic acids research, 2008, 36, 
5221-5231. 
22. G. Robertson, M. Hirst, M. Bainbridge, M. Bilenky, Y. Zhao, T. Zeng, G. Euskirchen, B. 
Bernier, R. Varhol, A. Delaney, N. Thiessen, O. L. Griffith, A. He, M. Marra, M. Snyder 
and S. Jones, Nature methods, 2007, 4, 651-657. 
135 
 
23. R. Blecher-Gonen, Z. Barnett-Itzhaki, D. Jaitin, D. Amann-Zalcenstein, D. Lara-Astiaso 
and I. Amit, Nature protocols, 2013, 8, 539-554. 
24. G. K. Marinov, Methods Mol Biol, 2017, 1543, 3-18. 
25. I. Cheung, H. P. Shulha, Y. Jiang, A. Matevossian, J. Wang, Z. Weng and S. Akbarian, 
Proceedings of the National Academy of Sciences of the United States of America, 2010, 
107, 8824-8829. 
26. Y. Kitagawa, N. Ohkura, Y. Kidani, A. Vandenbon, K. Hirota, R. Kawakami, K. Yasuda, 
D. Motooka, S. Nakamura, M. Kondo, I. Taniuchi, T. Kohwi-Shigematsu and S. Sakaguchi, 
Nature immunology, 2016, DOI: 10.1038/ni.3646. 
27. R. Mathur, B. H. Alver, A. K. San Roman, B. G. Wilson, X. Wang, A. T. Agoston, P. J. 
Park, R. A. Shivdasani and C. W. Roberts, Nature genetics, 2016, DOI: 10.1038/ng.3744. 
28. R. Hansel-Hertsch, D. Beraldi, S. V. Lensing, G. Marsico, K. Zyner, A. Parry, M. Di 
Antonio, J. Pike, H. Kimura, M. Narita, D. Tannahill and S. Balasubramanian, Nature 
genetics, 2016, 48, 1267-1272. 
29. S. Beyaz, J. H. Kim, L. Pinello, M. E. Xifaras, Y. Hu, J. Huang, M. A. Kerenyi, P. P. Das, 
R. A. Barnitz, A. Herault, R. Dogum, W. N. Haining, O. H. Yilmaz, E. Passegue, G. C. 
Yuan, S. H. Orkin and F. Winau, Nature immunology, 2016, DOI: 10.1038/ni.3644. 
30. M. de Dieuleveult, K. Yen, I. Hmitou, A. Depaux, F. Boussouar, D. Bou Dargham, S. 
Jounier, H. Humbertclaude, F. Ribierre, C. Baulard, N. P. Farrell, B. Park, C. Keime, L. 
Carriere, S. Berlivet, M. Gut, I. Gut, M. Werner, J. F. Deleuze, R. Olaso, J. C. Aude, S. 
Chantalat, B. F. Pugh and M. Gerard, Nature, 2016, 530, 113-116. 
31. A. Barski, S. Cuddapah, K. Cui, T.-Y. Roh, D. E. Schones, Z. Wang, G. Wei, I. Chepelev 
and K. Zhao, Cell, 2007, 129, 823-837. 
32. H. Yan, S. Tian, S. L. Slager, Z. Sun and T. Ordog, American journal of epidemiology, 
2016, 183, 96-109. 
33. A. R. Wu, J. B. Hiatt, R. Lu, J. L. Attema, N. A. Lobo, I. L. Weissman, M. F. Clarke and 
S. R. Quake, Lab on a chip, 2009, 9, 1365-1370. 
34. A. R. Wu and S. R. Quake, Cold Spring Harbor protocols, 2016, 2016, pdb prot084996. 
35. A. R. Wu, T. L. Kawahara, N. A. Rapicavoli, J. van Riggelen, E. H. Shroff, L. Xu, D. W. 
Felsher, H. Y. Chang and S. R. Quake, Lab on a chip, 2012, 12, 2190-2198. 
36. Z. Cao, C. Chen, B. He, K. Tan and C. Lu, Nature methods, 2015, 12, 959-962. 
37. Z. Cao and C. Lu, Analytical chemistry, 2016, 88, 1965-1972. 
38. T. W. Murphy, Y. P. Hsieh, S. Ma, Y. Zhu and C. Lu, Analytical chemistry, 2018, 90, 
7666-7674. 
39. S. Y. Teh, R. Lin, L. H. Hung and A. P. Lee, Lab on a chip, 2008, 8, 198-220. 
40. R. Seemann, M. Brinkmann, T. Pfohl and S. Herminghaus, Rep Prog Phys, 2012, 75, 
016601. 
41. A. Huebner, S. Sharma, M. Srisa-Art, F. Hollfelder, J. B. Edel and A. J. Demello, Lab on 
a chip, 2008, 8, 1244-1254. 
42. O. J. Dressler, R. M. Maceiczyk, S. I. Chang and A. J. deMello, Journal of biomolecular 
screening, 2014, 19, 483-496. 
43. C. N. Baroud, F. Gallaire and R. Dangla, Lab on a chip, 2010, 10, 2032-2045. 
44. G. F. Christopher and S. L. Anna, Journal of Physics D: Applied Physics, 2007, 40, R319-
R336. 
45. M. Leman, F. Abouakil, A. D. Griffiths and P. Tabeling, Lab on a chip, 2015, 15, 753-765. 
136 
 
46. M. Chabert and J. L. Viovy, Proceedings of the National Academy of Sciences of the United 
States of America, 2008, 105, 3191-3196. 
47. H. H. Gorris and D. R. Walt, Angew Chem Int Ed Engl, 2010, 49, 3880-3895. 
48. E. W. Kemna, R. M. Schoeman, F. Wolbers, I. Vermes, D. A. Weitz and A. van den Berg, 
Lab on a chip, 2012, 12, 2881-2887. 
49. D. J. Eastburn, A. Sciambi and A. R. Abate, Analytical chemistry, 2013, 85, 8016-8021. 
50. T. M. Tran, F. Lan, C. S. Thompson and A. R. Abate, Journal of Physics D: Applied 
Physics, 2013, 46, 114004. 
51. P. Garstecki, M. J. Fuerstman, H. A. Stone and G. M. Whitesides, Lab on a chip, 2006, 6, 
437-446. 
52. H. N. Joensson and H. Andersson Svahn, Angew Chem Int Ed Engl, 2012, 51, 12176-12192. 
53. L. Mazutis, J. Gilbert, W. L. Ung, D. A. Weitz, A. D. Griffiths and J. A. Heyman, Nature 
protocols, 2013, 8, 870-891. 
54. T. P. Lagus and J. F. Edd, Journal of Physics D: Applied Physics, 2013, 46, 114005. 
55. A. Rakszewska, J. Tel, V. Chokkalingam and W. T. S. Huck, NPG Asia Materials, 2014, 
6, e133. 
56. A. R. Abate, C. H. Chen, J. J. Agresti and D. A. Weitz, Lab on a chip, 2009, 9, 2628-2631. 
57. J. F. Edd, D. Di Carlo, K. J. Humphry, S. Koster, D. Irimia, D. A. Weitz and M. Toner, 
Lab on a chip, 2008, 8, 1262-1264. 
58. A. Rotem, O. Ram, N. Shoresh, R. A. Sperling, A. Goren, D. A. Weitz and B. E. Bernstein, 
Nature biotechnology, 2015, 33, 1165-1172. 
59. L. Mazutis and A. D. Griffiths, Lab on a chip, 2012, 12, 1800-1806. 
60. Y. Ding, X. C. i Solvas and A. deMello, The Analyst, 2015, 140, 414-421. 
61. A. Sciambi and A. R. Abate, Lab on a chip, 2015, 15, 47-51. 
62. V. Chokkalingam, Y. Ma, J. Thiele, W. Schalk, J. Tel and W. T. Huck, Lab on a chip, 2014, 
14, 2398-2402. 
63. E. Brouzes, A. Carniol, T. Bakowski and H. H. Strey, RSC advances, 2014, 4, 38542-38550. 
64. Y.-C. Tan, Y. L. Ho and A. P. Lee, Microfluidics and Nanofluidics, 2006, 3, 495-499. 
65. D. R. Link, S. L. Anna, D. A. Weitz and H. A. Stone, Physical Review Letters, 2004, 92. 
66. B. O'Donovan, T. Tran, A. Sciambi and A. Abate, Journal of visualized experiments : JoVE, 
2014, DOI: 10.3791/50913. 
67. L. M. Fidalgo, C. Abell and W. T. Huck, Lab on a chip, 2007, 7, 984-986. 
68. L. Li, J. Q. Boedicker and R. F. Ismagilov, Analytical chemistry, 2007, 79, 2756-2761. 
69. A. R. Abate, T. Hung, P. Mary, J. J. Agresti and D. A. Weitz, Proceedings of the National 
Academy of Sciences of the United States of America, 2010, 107, 19163-19166. 
70. P. Tabeling, Lab on a chip, 2009, 9, 2428-2436. 
71. S. Ma, J. M. Sherwood, W. T. Huck and S. Balabani, Lab on a chip, 2014, 14, 3611-3620. 
72. J. D. Tice, H. Song, A. D. Lyon and R. F. Ismagilov, Langmuir, 2003, 19, 9127-9133. 
73. T. H. Ho, R. N. Nateras, H. Yan, J. G. Park, S. Jensen, C. Borges, J. H. Lee, M. D. 
Champion, R. Tibes, A. H. Bryce, E. M. Carballido, M. A. Todd, R. W. Joseph, W. W. 
Wong, A. S. Parker, M. L. Stanton and E. P. Castle, PloS one, 2015, 10, e0132831. 
74. M. F. Carey, C. L. Peterson and S. T. Smale, Cold Spring Harbor protocols, 2009, 4, 
doi:10.1101/pdb.prot5279. 
75. T. I. Lee, S. E. Johnstone and R. A. Young, Nature protocols, 2006, 1, 729-748. 




Chapter 6 Conclusions and Future Work 
 
The previous chapters described automated sample processing for three different 
epigenomic assays (MNase-seq, MBA-seq, and ChIP-seq) using droplet microfluidics. The 
feasibility of these developed methodology has been characterized and validated. More needs to 
be completed to further improve these platforms’ performance and verify their applicability in 
clinical settings in order to utilize these techniques for epigenomic diagnostics and therapeutics 
eventually. 
Nucleosome Preparation from Clinical Samples for MNase-seq 
Chapter 3 validated the MNase-processing device’s efficacy in preparing qualified samples 
for MNase-seq with immortal cell line cells. Whether this strategy works with clinical samples 
need to be confirmed for practical considerations. Preliminary data of patient studies using this 
droplet microfluidic platform has been collected by processing buffy coat. Buffy coat is a 
representative of clinically-relevant patient sample as it is a major component of whole blood 
without red blood cells or plasma.1 The buffy coat collection method for this thesis was described 
in Chapter 4. Flow rates, MNase concentrations, and cell suspension conditions were the same as 
the optimal ones in Chapter 3. The selected disease model was septic shock, a subset of sepsis 
where after causing organ dysfunctions the widespread, dysregulated host responses to infection 
are drastically severe to induce increased risk of mortality.2 Sepsis and septic shock have been 
recognized as global health issues and remained as one of the leading causes of in-hospital deaths 
in the USA (between 33% and 50%).2 Moreover, sepsis and septic shock have complicated gene 
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expression regulating networks during the progress, thus increasing efforts are being made to 
further decipher the disease so that reliable diagnostic marks and therapeutic targets can be 
discovered to offer an improved, urgent, and correct clinical care of septic patients.3 With the goal 
to discover the underlying nucleosome positioning mechanisms in septic shock, the buffy coat 
samples from septic shock patients, matched non-septic shock patients, and healthy controls were 
processed with the platform developed in Chapter 3. Figure 6-1 confirmed the successful droplet 
microfluidic processing of buffy coat samples extracted from whole blood from five pairs of 
matched septic and non-septic shock patients, and three healthy controls (duplicates each patient, 
thus twenty-six samples processed on chip or off chip/in tube, fifty-two samples processed in total). 
Mononucleosome yields of all samples were consistent with the characterization results generated 
from Jurkat cells in Chapter 3 at around 80%, not significantly different from those off-chip 
controls mimicking the on-chip conditions, indicating no bias was induced by the device but only 
the biology of MNase contributed to the success of sample preparation. These samples were also 
sequenced and bioinformatic analysis is undergoing. Preliminary results from part of the patient 





Figure 6-2 showed the counted nucleosomes from libraries prepared from buffy coat 
mononucleosomal DNA processed on the device (“on”) and in the tube mimicking on-chip 
conditions (“in”). Like the results shown in Figure 3-16, similar numbers of nucleosomes were 
counted in all samples, proving little bias existed in the droplet microfluidic platform. The absolute 
values of nucleosome peaks also fit with the theoretical number of nucleosome in human genome. 
This proved that clinical-relevant samples processed by the developed droplet microfluidic 
platform are capable of generating qualified sequencing results for further interpretation, which in 
Figure 6-1 Mononucleosome yields of buffy coat samples processed on the device developed in 
Chapter 3 and in tube as controls. For each group of data, scattered dots of all data were on the 
left, and box plots with mean and one standard deviation as whiskers were on the right. Each data 
point represented the result of one sample containing 125,000 cells in 30-µL density-adjusted PBS. 
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turn verified the potential of integrating this platform to clinical routine to assist the promotion of 
epigenetic diagnosis and therapy development.  
 Figure 6-3 showed the nucleosome positioning surrounding TSSs of all genes of the 
replicate samples from 0620A and B patients. Again, the high correlation of the peak and valleys 
of the nucleosome levels between on-chip duplicates and between on-chip and off-chip (in-tube) 
processed samples proved little bias was introduced by the microfluidic system and the samples 
were showing data that match with precedent literatures: well-positioned nucleosomes right up-
stream and down-stream of TSSs and more fuzzier distribution going to the gene body.4 
Interestingly, the profile shapes of normalized nucleosome read density around TSSs of all genes 
were also similar between matched patients of septic shock and non-septic shock patients (Figure 
6-4, from left to right were results of sample pairs collected on 0522, 0620, and 0628, respectively), 
while further IPA analysis (Ingenuity Pathway Analysis, QIAgen) showed that only a small 
number of genes (~100) of these two types of patients encountered dynamic nucleosomes within 
2kb of TSSs including FOXP1 (related to quiescence of CD4+ T lymphocytes), FN1 (related to 
response to ischemia), and FOS4 (related to inflammatory response such as cytokine signaling and 
multiple immune system signaling pathways) indicating that the accessibility to these genes’ 
promoter regions were being regulated and changed comparing these two conditions. Therefore, 
perhaps only a few genes were functioning as the driving forces or results of the immune system’s 
response to the widespread infection and inflammation in septic shock condition. If validated with 
a large-scale data set collected from more patients, this would be extraordinarily exciting from the 





Figure 6-2 Nucleosomes counted in each library constructed from buffy coat mononucleosomal 
DNA prepared by the Chapter 3 device or in tube. The sample names were formatted as collected 
date followed by either “on” (on chip) or “in” (in tube, or off chip) with sample number and 
replicate number. The last number was library number when constructing them for sequencing 








Figure 6-3 Normalized nucleosome read density surrounding TSSs of buffy coat extracted from 
whole blood of patients labeled as 0620A and 0620B, the latter being the septic shock patient. 
Notice the high correlation of the peak and valley of nucleosome levels among the one in-tube 
processed replicate and two on-chip processed replicates of each patient.  
Figure 6-4 Normalized nucleosome read density surrounding TSSs of buffy coat extracted from 
whole blood of three pairs of patients. Notice the high correlation of the peak and valley of 
nucleosome levels between each matched pair.  
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These preliminary results showed promising future in elucidating epigenomic regulation 
changes in septic shock from the perspective of nucleosome positioning using the droplet 
microfluidic device developed in Chapter 3. Besides the completion of the bioinformatic analysis 
of samples from the other two pairs of patients and healthy controls, more patients need to be 
enrolled to collect “big data” to ensure the fidelity of the diagnosing insights summarized from the 
nucleosome mapping and identifying affected genes in septic shock. Moreover, septic shock can 
be the deadly result of the worsened sepsis development. Nucleosome positioning profiling along 
the time trajectory of sepsis patients’ disease development can reveal more precious information 
of the mechanisms in epigenetic regulation of immune-related gene expression as sepsis develops 
so that involved epigenetic marks along with the regulated genes can be identified as prognostic 
marks in future septic diagnosis and treatment to predict the patients with higher risks of turning 
into septic shock in order to take better care of them. Therefore, processing the buffy coat from 
the same patients at different septic developing stages is highly expected as well to further the 
investigation. Furthermore, patients recovered from sepsis or septic shock may have changed 
epigenetic profiles casting long-term effects on their immune systems.5 Thus, continuous sample 
collections and nucleosome positioning studies via tracking septic shock survivors for a certain 
duration of time should also be included in the long-term goal of this project to fully understand 
the epigenetic regulating mechanisms and related long-lasting impact involved in the process. 
Additionally, the device developed in Chapter 3 also processed porcine buffy coat 
efficiently as shown in Figure 6-5. The porcine buffy coat was from a pig model introduced with 
sepsis. Whole blood samples were collected at 4 different time points and buffy coat extracted 
within 8 hours after the blood collected. The consistent native cell chromatin digestion efficiency 
showed that this developed platform has wide applicability in nucleosome positioning studies on 
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different subjects. Therefore, if time trajectory studies of human patients are challenging, animal 




Figure 6-5 Mononucleosome yields of porcine buffy coat samples processed on the device 
developed in Chapter 3 and in tube as controls. For each group of data, scattered dots of all data 
were on the left, and box plots with mean and one standard deviation as whiskers were on the right. 




Further Optimization of Device Design to Collect Linker DNA for MBA-seq 
Chapter 4 described a droplet microfluidic device that can provide two samples for two 
different epigenomic assays from the same batch of sample cells through passive aliquoting the 
generated droplets containing cells and MNase to two directions for different lengths of digestion 
time duration. Although the preliminary data proved success in enriching nucleosome-free linker 
DNA regions, more aspects can be improved.  
First, active mechanisms to control sample aliquoting may be included to replace the 
current passive mechanism. Current mechanism simply relies on the bifurcating design to direct 
droplets to two directions. Thus, the ratio of droplets going to MBA side versus droplets going to 
MNase side is determined by the pressure drop difference between the two routes, which also 
determine the delay time on each side. This means anything that can disrupt the pressure drop in 
either branch such as a PDMS fiber or a piece of dust might affect the droplet aliquoting ratio and 
thus the DNA yield on each side. Therefore, if an active aliquoting mechanism such as valves can 
be integrated to the platform, quantitative percentage of the sample plug can be directed to either 
side, leading to a more accurate control of DNA amount on both sides.  
Second, digestion for MBA-seq DNA can be controlled by lowering MNase concentration 
rather than the current strategy, which is shortening delay time. Although current strategy was 
proved to be working, it requires two branches of delay channels of different lengths and 
thicknesses in order to ensure the appropriately short digestion time for MBA DNA and long 
enough digestion time for MNase DNA. The device footprint was not compacted enough. Figure 
6-6 proved that 0.2×MNase (i.e., 4% of the current MNase concentration) digesting 50-µL, 5 
million per mL cells for 210 s in tube generated qualified MBA DNA with significant enrichment 
of both positive loci tested by qPCR. This indicated the applicability of starting with low MNase 
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concentration to digest for MBA DNA and increasing the concentration to the current level to 
collect for MNase DNA with the same delay channel. In this situation, the device footprint could 
be reduced and additionally, the aliquoting ratio of samples between the two assays can be 
controlled by the timing increasing MNase concentration. Notice that even though shorter 
digestion time (<210 s) at lower concentration of MNase yielded more qualified MBA DNA with 
higher enrichment on both loci, it would not be different from the current design to have two 
different lengths of delay channels if adopting those conditions. Moreover, as long as the 
enrichment reaches the empirical threshold (fold change ≥ 5), the MBA DNA should be able to 





Optimization and Automation of Droplet Microfluidic ChIP Workflow 
As discussed in Chapter 5, current ChIP workflow needs more optimization to obtain 
efficient ChIP DNA from on-chip processing. Besides the necessity to optimize bead loading and 
droplet sorting, more parts of the entire ChIP workflow needs to be automated. Figure 6-7 
illustrated the proposed droplet ChIP workflow. Module 1 has been completed with slight 
modification (simultaneous lysis and digestion in Chapter 3). Module 2 is under development with 
Figure 6-6 Fold change expressed in the format of ∆∆Ct (i.e., log2(fold change)) of all devices 
tested in Chapter 4 as well as in-tube test with lower concentration of MNase and shorter digestion 
time. Notice the similar performance of samples processed by 0.2×MNase and digested for 210 s 




the efforts described in Chapter 5. Module 3 needs to be started as RNase A and Proteinase K 
treatment takes several hours to complete before DNA can be purified. Automating this step on 
droplet microfluidic platform will benefit not only ChIP assay but also MNase-seq assay and many 
other chromatin-based epigenomic assays. A proposed strategy is adapted from a cylindrical heater 
for real-time PCR6 and the modified version is shown in Figure 6-8. The heater was fabricated by 
the electronic shop in the department of chemistry. Droplet collecting tubing was wrapped around 
the heater set at 65°C to activate RNase A and Proteinase K. Currently the strategy is to add these 
two enzymes simultaneously to the quenching buffer and inject to the droplets containing digested 
chromatin or antibody-bead conjugate bound chromatin after wash. Preliminary data showed the 
applicability of this strategy, and more experiments need to be done to optimize the performance 






Figure 6-7 Proposed droplet ChIP workflow to be completed.  
Figure 6-8 In-house fabricated cylindrical heater for integrated RNase A and Proteinase K 
treatment of chromatin using droplet microfluidics.  
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 Moreover, currently the droplet ChIP is native ChIP (N-ChIP), processing cells without 
fixation. N-ChIP provides qualified data when the targets are histone modification marks, as the 
nucleosome structures are stable; however, if the targets are transiently bound proteins to 
functional DNA regions, it is better to fix the cells to preserve the binding event of such short-term 
binding proteins such as transcriptional factors through covalent bonds (X-ChIP).7 Therefore, 
validating X-ChIP on the same droplet microfluidic platform will also be significant to broaden 
the application fields for the proposed droplet ChIP strategy.  
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Figure A-1 Photomask of the MNase processing device design after translating AutoCAD files 







Figure A-2 A representative of non-selected device design for MBA/MNase-seq sample 
preparation in Chapter 4. The shown design was named “4R”, as it contained 4 rows of thick, 160-





Biological Related Information and Results 
Table B-1 Sequences of primer pairs for the positive and reference loci used in the MBA/MNase 
device development in Chapter 4. 
Primer name Sequences (5’ to 3’) 
CD47 enhancer forward primer TGATGACACCGGTGATATGGT 
CD47 enhancer reverse primer GGCATTTTATCTTCCACTCTCCC 
DZIP3 forward primer CTCTGCATAACCACTAGGTGGCA 
DZIP3 reverse primer TTTTTAAACAAGTGCAGTCGTGTGG 
C19 intergenic forward primer AGCTTGTCTTTCCCAAGTTTACTC 




















Figure B-1 Mononucleosome yields from all Jurkat samples processed for sequencing with the 
data points illustrated on the left and corresponding box plots on the right for both on-chip and off-
chip samples. Each sample was 50-µL suspension containing 500,000 cells. The whiskers of the 
box plots represented one standard deviation. The top and bottom box limits represented third and 
first quantiles of the corresponding data. The lines in the middle of the boxes represented means 















Figure B-2 Digestion pattern of K-562 cells MBA DNA of one replicate. Notice only a small 
peak < 250 bp existed in MBA DNA while majority was at higher base pair approaching to the 
higher internal standard, in this case the “mono ratio” was 9.2%. Level of digestion similar to 
this was expected to be qualified for the limited digestion to preserve linker DNA or nucleosome-
free accessible regions. The two high peaks were internal standards at 35 bp and 10380 bp, 
respectively. The green and blue dashes were location cursors of the Bioanalyzer software, which 












Figure B-3 Digestion pattern of K-562 cells MNase DNA of one replicate. Notice that majority 
of the DNA was digested to mononucleosomal length with only small di-nucleosome peak. Level 
of digestion similar to or higher than this was expected to be qualified for MNase-seq. The two 
high peaks were internal standards at 35 bp and 10380 bp, respectively. The green and blue dashes 

















Figure B-4 Digestion pattern of buffy coat cells MBA DNA of one replicate. Notice only a 
small peak < 250 bp existed in MBA DNA while majority was at higher base pair approaching 
to the higher internal standard, in this case the “mono ratio” was 21%. Level of digestion 
similar to this was expected to be qualified for the limited digestion to preserve linker DNA or 
nucleosome-free accessible regions. The two high peaks were internal standards at 35 bp and 
10380 bp, respectively. The green and blue dashes were location cursors of the Bioanalyzer 

















Figure B-5 Digestion pattern of buffy coat cells MNase DNA of one replicate. Notice that majority 
of the DNA was digested to mononucleosomal length with only small di-nucleosome peak. Level 
of digestion similar to or higher than this was expected to be qualified for MNase-seq. The two 
high peaks were internal standards at 35 bp and 10380 bp, respectively. The green and blue dashes 
were location cursors of the Bioanalyzer software, which had no effect on the profile.  
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Table B-2 Sequences of primer pairs for the targeted and reference loci used in the development 
of droplet microfluidic ChIP in Chapter 5. 
Primer name Sequences (5’ to 3’) 
Brg1_TSS forward primer TTGGCGAAGCTGCGATCGGG 
Brg1_TSS reverse primer AGGGGACCGCTAATGCCCGT 
MYT1_TSS forward primer CCTGCCGTGTGCTGTTTTT 
MYT1_TSS reverse primer CACAACATGTCCCCTGGAATC 
SAT-alpha forward primer AAGGTCAATGGCAGAAAAGAA 
SAT-alpha reverse primer CAACGAAGGCCACAAGATGTC 
C19 intergenic forward primer AGCTTGTCTTTCCCAAGTTTACTC 
































Figure B-6 Digestion pattern of the input sample used in ChIP in tube mimicking on-chip 
conditions targeting H3K4me3. Notice that majority of the DNA was digested to 
mononucleosomal length with only small di-nucleosome peak. Mono peak consisted of 80.6% 
of the entire digestion profile. The two high peaks were internal standards at 35 bp and 10380 
bp, respectively. The green and blue dashes were location cursors of the Bioanalyzer software, 







Figure B-7 Fold change results of ChIP using 2-µg anti-H3K27me3 antibody per reaction. 
15uL_IP10_1 stood for ChIP with 15-µL Dynabead slurry, incubating 10 minutes for 
immunoprecipitation, replicate 1. “ov” stood for ChIP overnight. The 1% input came from 
preparing enough aliquots of fragmented chromatin for each ChIP reaction together and took 1% 
out of one aliquot of chromatin from that. BRG1 stood for fold change of Brg1_TSS normalized 
to C19_intergenic in ChIP DNA compared to the input sample F3_1_1%inp, MYT1 stood for 
fold change of Myt1_TSS normalized to C19_intergenic, hSAT stood for fold change of SAT-
alpha normalized to C10_intergenic. Notice the highest fold change of Myt1_TSS and similar 
fold change of the other two non-specific loci obtained in the condition of 30-µL Dynabead slurry 
incubating overnight. This condition was the one described as “ChIP in tube mimicking on-chip 
conditions”. Fold changes of three gene loci all close to 1 in 100% input showed that the 
chromatin fragmentation was consistent across replicates and parts of replicates, showing that 
















Figure B-8 Digestion pattern of the F3_1_1%inp input sample used in ChIP of three formats. 
Notice that majority of the DNA was digested to mononucleosomal length with only small di-
nucleosome peak. Mono peak counting from 75 bp to 235 bp consisted of 74.1% of the entire 
digestion profile. The two high peaks were internal standards at 35 bp and 10380 bp, 
respectively. The green and blue dashes were location cursors of the Bioanalyzer software, 















Figure B-9 Digestion pattern of the F3_2_1%inp input sample used in ChIP of three formats. 
Notice that majority of the DNA was digested to mononucleosomal length with only small di-
nucleosome peak. Mono peak counting from 75 bp to 235 bp consisted of 71.8% of the entire 
digestion profile. The two high peaks were internal standards at 35 bp and 10380 bp, respectively. 
The green and blue dashes were location cursors of the Bioanalyzer software, which had no effect 




Figure B-10 Digestion pattern of the In_100%inp input sample used in ChIP of three formats. 
Notice that majority of the DNA was digested to mononucleosomal length with only small di-
nucleosome peak. Mono peak counting from 75 bp to 235 bp consisted of 66.2% of the entire 
digestion profile. The two high peaks were internal standards at 35 bp and 10380 bp, 
respectively. The green and blue dashes were location cursors of the Bioanalyzer software, 
which had no effect on the profile. 
